var title_f39_33_40464="Mitral inflow annular ratio";
var content_f39_33_40464=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mitral inflow to annular ratio",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 339px; height: 365px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A shows the four chamber view of the two dimensional echocardiogram and panel B is the pulsed Doppler image. The mitral inflow to annular ratio (E/Ea) is obtained using routine pulsed-Doppler of the mitral inflow and pulsed-tissue Doppler of the lateral mitral annulus.",
"    <div class=\"footnotes\">",
"     E: peak early diastolic mitral inflow velocity; Ea: peak early diastolic mitral annular velocity.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_33_40464=[""].join("\n");
var outline_f39_33_40464=null;
var title_f39_33_40465="Thumbs up sign for radial nerve motor function";
var content_f39_33_40465=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Thumbs up sign for radial nerve motor function",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Motor function of the radial nerve can be tested by asking the patient to make the thumbs up sign, as shown in the photograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_33_40465=[""].join("\n");
var outline_f39_33_40465=null;
var title_f39_33_40466="Finger flexor power Doppler";
var content_f39_33_40466=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F63571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F63571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Finger flexor power Doppler sonogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This power Doppler sonogram shows a longitudinal cut of a finger flexor tenosynovitis at the third proximal interphalangeal joint (PIP 3), showing signs of inflammation, including tendon contour irregularity, sheath widening, sheath thickening, surrounding anechoic fluid, and positive power Doppler signal (red and orange areas).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of George AW Bruyn, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_33_40466=[""].join("\n");
var outline_f39_33_40466=null;
var title_f39_33_40467="Palpable purpura legs";
var content_f39_33_40467=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Palpable purpura",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Palpable purpura are present on the legs of this patient with cutaneous small vessel vasculitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:",
"     <a href=\"file://www.visualdx.com\" target=\"_blank\">",
"      www.visualdx.com",
"     </a>",
"     . Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_33_40467=[""].join("\n");
var outline_f39_33_40467=null;
var title_f39_33_40468="Ipilimumab: Patient drug information";
var content_f39_33_40468=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ipilimumab: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/52/19270?source=see_link\">",
"     see \"Ipilimumab: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12743392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Yervoy&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14225438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Yervoy&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12724842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3411935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause swelling of the bowels that may lead to tears or holes. Call your doctor if you have loose stools, blood in your stool, or very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700734",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause liver problems. Call your doctor if you see dark urine, feel tired, are not hungry, have an upset stomach, are throwing up, or have yellowing of the skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad rashes have been reported. Talk with your doctor right away if you get a rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3411937",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause very bad nerve problems that may lead to not being able to move a part of the body (paralysis). Call your doctor if you have numbness, tingling, or weakness in your arms or legs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3411938",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may change hormone levels in the body. Call your doctor if you have headaches, change in mood, dizziness, passing out, feeling cold, or weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F12724903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F12724817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3411945",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ipilimumab or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F12724819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697158",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an autoimmune disease such as rheumatoid arthritis or lupus, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3414828",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a kidney transplant, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F12724906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698306",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rash.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F12724821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699035",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad mouth irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F12724905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F12724822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16460 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-1A240FD273-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_33_40468=[""].join("\n");
var outline_f39_33_40468=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12743392\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14225438\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12724842\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12724903\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12724817\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12724819\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12724906\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12724821\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12724905\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12724822\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?18/52/19270?source=related_link\">",
"      Ipilimumab: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_33_40469="Calcium channel blockers in the management of acute coronary syndrome";
var content_f39_33_40469=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Calcium channel blockers in the management of acute coronary syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/33/40469/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/33/40469/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/33/40469/contributors\">",
"     Harold L Kennedy, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/33/40469/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/33/40469/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/33/40469/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/33/40469/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/33/40469/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium channel blockers were initially advocated for use in patients with an acute myocardial infarction (MI) based upon theoretical arguments that they would limit the extent of myocardial necrosis in peri-infarct ischemic zones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40469/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. There was also a misperception regarding the prevalence of coronary vasospasm as the precipitant of MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40469/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Numerous studies have investigated the possible mortality benefit of calcium channel blockers after acute MI. The important trials and any possible role for these drugs in this setting will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SHORT-ACTING NIFEDIPINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-acting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    has been studied in the acute and subacute phase of myocardial infarction for both short- and long-term use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40469/abstract/5-12\">",
"     5-12",
"    </a>",
"    ]. Initial trials, such as TRENT in suspected MI and SPRINT I in the subacute phase of acute MI, found neither benefit nor harm with short-acting nifedipine compared to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40469/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. However, a number of other trials evaluating patients at different time periods found increased mortality in patients treated with short-acting nifedipine compared to placebo (",
"    <a class=\"graphic graphic_figure graphicRef74199 \" href=\"mobipreview.htm?40/59/41916\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40469/abstract/7,8,10\">",
"     7,8,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an early trial, 171 patients with a threatened or acute MI were randomly assigned to short-acting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    (20 mg every four hours) or placebo for 14 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40469/abstract/8\">",
"     8",
"    </a>",
"    ]. Nifedipine therapy had no effect on progression to MI in patients with threatened MI or on infarct size in patients with acute MI. However, mortality at 14 days was significantly increased with nifedipine (7.9 versus 0 percent), an effect that was no longer significant at six months.",
"   </p>",
"   <p>",
"    The subsequent SPRINT II trial investigated early therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    (usually within three hours of admission for suspected acute MI) that was continued for up to six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40469/abstract/7\">",
"     7",
"    </a>",
"    ]. In the 1000 patients assigned to receive either nifedipine (60",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo, there was a trend toward",
"    <strong>",
"     increased",
"    </strong>",
"    mortality in the nifedipine group (18.7 versus 15.6 percent with placebo). This increase in mortality occurred in the first six days of therapy; mortality was equal in both groups for the remaining follow-up period. A smaller study showed a similar increase in early deaths with nifedipine, which was negated by fewer deaths at the six month follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40469/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These trials have provided part of the rationale for the now rare use of short-acting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    . The increase in risk in some patients is thought to be mediated at least in part by repeated episodes of hypotension and reflex sympathetic activation, changes that are not generally seen with long-acting drugs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32966?source=see_link&amp;anchor=H9#H9\">",
"     \"Major side effects and safety of calcium channel blockers\", section on 'Serious adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The excess early mortality with short-acting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    in some patients with acute MI (",
"    <a class=\"graphic graphic_figure graphicRef74199 \" href=\"mobipreview.htm?40/59/41916\">",
"     figure 1",
"    </a>",
"    ) has led to the recommendation that this drug should be avoided. This conclusion is consistent with that reached in studies in patients with stable coronary heart disease in which mortality was increased after treatment with short-acting nifedipine, particularly at high doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40469/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32966?source=see_link&amp;anchor=H10#H10\">",
"     \"Major side effects and safety of calcium channel blockers\", section on 'Increased mortality after acute MI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increase in risk is thought to be mediated at least in part by repeated episodes of hypotension and reflex sympathetic activation, changes that are not generally seen with long-acting drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DILTIAZEM AND VERAPAMIL",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to dihydropyridines, the nondihydropyridine calcium channel blockers",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    slow heart rate and may have a limited role in preventing nonfatal reinfarction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diltiazem",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     Diltiazem",
"    </a>",
"    has been evaluated in clinical trials of patients with an acute MI, with the exception that no trials have been performed in patients treated with percutaneous coronary intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     MDPIT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Multicenter",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     Diltiazem",
"    </a>",
"    Postinfarction Trial (MDPIT) randomly assigned 2466 patients who were 3 to 15 days after an acute ST elevation or non-ST elevation MI to diltiazem (240",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40469/abstract/14\">",
"     14",
"    </a>",
"    ]. After a mean follow-up of 25 months, the mortality in the two groups was identical (13.5 percent) although the recurrent event rate (cardiac death and nonfatal reinfarction) was nonsignificantly lower in patients treated with diltiazem (16.4 versus 18.3 percent). However, since beta blockers were given to some patients in the diltiazem group, it is unclear which drug was responsible for the favorable result.",
"   </p>",
"   <p>",
"    Left ventricular function was an important variable in MDPIT.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     Diltiazem",
"    </a>",
"    reduced the number of cardiac events (hazard ratio 0.77) in a subgroup with preserved left ventricular function (no pulmonary congestion on chest x-ray or left ventricular ejection fraction above 40 percent). By contrast, patients with impaired left ventricular function (pulmonary congestion on chest x-ray or LVEF &le;0.40) who were treated with diltiazem had a higher cardiac event rate (hazard ratio 1.41) and higher cardiac mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40469/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The MDPIT study (ST and non-ST elevation MI) and the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     Diltiazem",
"    </a>",
"    Reinfarction Study (non-ST elevation MI) have suggested that the benefit of diltiazem on cardiac event rates and cardiac mortality is more apparent in non-ST elevation MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40469/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     INTERCEPT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The INTERCEPT trial enrolled 874 patients with an ST elevation MI, but without heart failure, who were treated with a thrombolytic agent; the patients were randomly assigned to oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    (300 mg daily) or placebo within 36 to 96 hours of symptom onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40469/abstract/18\">",
"     18",
"    </a>",
"    ]. There was no significant difference in the primary end point (first event rate of cardiac death, nonfatal reinfarction, or refractory ischemia) at six-month follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Intravenous diltiazem",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most of the clinical studies with calcium channel blockers involve long-term therapy, experimental data suggest that calcium channel blockers might have their greatest effect when administered early during ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40469/abstract/19\">",
"     19",
"    </a>",
"    ]. In an attempt to address this issue, a pilot study randomly assigned 59 patients with an acute ST elevation MI treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    , to intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    or placebo for 48 hours, followed by oral therapy for four weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40469/abstract/20\">",
"     20",
"    </a>",
"    ]. Compared to placebo, diltiazem significantly reduced the rate of death, reinfarction, or recurrent ischemia at 35 days (13 versus 41 percent), primarily due to a reduction in recurrent ischemia, and prevented the need for urgent revascularization (0 versus 27 percent). However, side effects requiring transient or permanent drug discontinuation were more common with diltiazem (27 versus 17 percent for placebo).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Verapamil",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     DAVIT II trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the DAVIT II trial, almost 1800 patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    (360",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo in the second week after admission for an acute MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40469/abstract/21\">",
"     21",
"    </a>",
"    ]. Patients treated with verapamil had nonsignificant reductions in both total mortality (11.1 versus 13.8 percent) and major cardiac events (18.0 versus 21.6 percent). Similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    in MDPIT, verapamil reduced mortality and the major event rate (14.6 versus 19.7 percent) in the subset of patients without heart failure. In contrast, verapamil had no effect upon mortality or event rate in those with heart failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     CRIS trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CRIS trial randomly assigned 1073 patients with an acute MI to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    retard (360",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo 7 to 21 days after the MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40469/abstract/22\">",
"     22",
"    </a>",
"    ]. At two years follow-up, there were no differences between the groups in total deaths or cardiac deaths; there was a nonsignificant trend toward fewer recurrent infarctions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SECOND GENERATION DIHYDROPYRIDINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     Amlodipine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/45/2775?source=see_link\">",
"     felodipine",
"    </a>",
"    are long-acting second generation dihydropyridines that have vascular smooth muscle relaxing activity but no negative inotropic effects. These drugs have not been examined directly in patients with an acute MI. Clinical trials that evaluated these drugs in heart failure (V-HeFT III and the PRAISE trials) and stable coronary heart disease (PREVENT trial) found no or little benefit but also no harm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30438?source=see_link\">",
"     \"Calcium channel blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the limited data in acute MI, these agents, particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    , are often used in such patients when hypertension is not adequately controlled by other therapies of proven benefit (eg, beta blockers and angiotensin converting enzyme inhibitors or angiotensin II receptor blockers).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available evidence suggests that calcium channel blockers have a limited role in the management of patients with acute myocardial infarction.",
"   </p>",
"   <p>",
"    We agree with conclusions reached in the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on NSTEMI and STEMI, which emphasized that no calcium channel blocker has been shown to reduce mortality in acute MI and that in certain patients they may be harmful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40469/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Specifically, the use of short-acting dihydropyridines such as immediate release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    , and the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    in patients with heart failure, LV systolic dysfunction, or significant atrioventricular block, has been associated with worse outcomes.",
"   </p>",
"   <p>",
"    We suggest using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    , in addition to other beneficial interventions, in patients with MI who have ongoing or recurring ischemia and who do not have LV dysfunction, heart failure or atrioventricular block when beta blockers are absolutely contraindicated (active bronchospasm or allergy) (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    We suggest using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    in patients with STEMI for the short term control of rapid ventricular response in atrial fibrillation or atrial flutter, in the absence of LV dysfunction or heart failure, when beta blockers are absolutely contraindicated or ineffective (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40469/abstract/1\">",
"      Braunwald E. Mechanism of action of calcium-channel-blocking agents. N Engl J Med 1982; 307:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40469/abstract/2\">",
"      Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin Invest 1985; 76:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40469/abstract/3\">",
"      Oliva PB, Breckinridge JC. Arteriographic evidence of coronary arterial spasm in acute myocardial infarction. Circulation 1977; 56:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40469/abstract/4\">",
"      Maseri A, L'Abbate A, Baroldi G, et al. Coronary vasospasm as a possible cause of myocardial infarction. A conclusion derived from the study of \"preinfarction\" angina. N Engl J Med 1978; 299:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40469/abstract/5\">",
"      Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ 1989; 299:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40469/abstract/6\">",
"      Wilcox RG, Hampton JR, Banks DC, et al. Trial of early nifedipine in acute myocardial infarction: the Trent study. Br Med J (Clin Res Ed) 1986; 293:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40469/abstract/7\">",
"      Goldbourt U, Behar S, Reicher-Reiss H, et al. Early administration of nifedipine in suspected acute myocardial infarction. The Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study. Arch Intern Med 1993; 153:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40469/abstract/8\">",
"      Muller JE, Morrison J, Stone PH, et al. Nifedipine therapy for patients with threatened and acute myocardial infarction: a randomized, double-blind, placebo-controlled comparison. Circulation 1984; 69:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40469/abstract/9\">",
"      Secondary prevention reinfarction Israeli nifedipine trial (SPRINT). A randomized intervention trial of nifedipine in patients with acute myocardial infarction. The Israeli Sprint Study Group. Eur Heart J 1988; 9:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40469/abstract/10\">",
"      Koenig W, L&ouml;wel H, Lewis M, H&ouml;rmann A. Long-term survival after myocardial infarction: relationship with thrombolysis and discharge medication. Results of the Augsburg Myocardial Infarction Follow-up Study 1985 to 1993. Eur Heart J 1996; 17:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40469/abstract/11\">",
"      Ishikawa K, Nakai S, Takenaka T, et al. Short-acting nifedipine and diltiazem do not reduce the incidence of cardiac events in patients with healed myocardial infarction. Secondary Prevention Group. Circulation 1997; 95:2368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40469/abstract/12\">",
"      Doppler flow and echocardiography in functional cardiac insufficiency: assessment of nisoldipine therapy. Results of the DEFIANT-II Study. The DEFIANT-II Research Group. Eur Heart J 1997; 18:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40469/abstract/13\">",
"      Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40469/abstract/14\">",
"      The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. N Engl J Med 1988; 319:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40469/abstract/15\">",
"      Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation 1991; 83:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40469/abstract/16\">",
"      Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. N Engl J Med 1986; 315:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40469/abstract/17\">",
"      Boden WE, Kleiger RE, Gibson RS, et al. Favourable long term prognosis in patients with non-Q wave acute myocardial infarction not associated with specific electrocardiographic changes. Diltiazem Reinfarction Study Research Group. Br Heart J 1989; 61:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40469/abstract/18\">",
"      Boden WE, van Gilst WH, Scheldewaert RG, et al. Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT). Lancet 2000; 355:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40469/abstract/19\">",
"      Przyklenk K, Kloner RA. Effect of verapamil on postischemic \"stunned\" myocardium: importance of the timing of treatment. J Am Coll Cardiol 1988; 11:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40469/abstract/20\">",
"      Th&eacute;roux P, Gr&eacute;goire J, Chin C, et al. Intravenous diltiazem in acute myocardial infarction. Diltiazem as adjunctive therapy to activase (DATA) trial. J Am Coll Cardiol 1998; 32:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40469/abstract/21\">",
"      Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II). Am J Cardiol 1990; 66:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40469/abstract/22\">",
"      Rengo F, Carbonin P, Pahor M, et al. A controlled trial of verapamil in patients after acute myocardial infarction: results of the calcium antagonist reinfarction Italian study (CRIS). Am J Cardiol 1996; 77:365.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson J, Adams C, Antman E, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College or Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007; 50:e1 www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007). www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 98 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-9CEA1CDAAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_33_40469=[""].join("\n");
var outline_f39_33_40469=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SHORT-ACTING NIFEDIPINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DILTIAZEM AND VERAPAMIL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diltiazem",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - MDPIT trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - INTERCEPT trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Intravenous diltiazem",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Verapamil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - DAVIT II trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - CRIS trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SECOND GENERATION DIHYDROPYRIDINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/98\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/98|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/59/41916\" title=\"figure 1\">",
"      Calcium blockers post MI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30438?source=related_link\">",
"      Calcium channel blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32966?source=related_link\">",
"      Major side effects and safety of calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_33_40470="ECG tetralogy of Fallot";
var content_f39_33_40470=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 473px\">",
"   <div class=\"ttl\">",
"    Electrocardiagram from an infant with tetralogy of Fallot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 453px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The ECG in tetralogy of Fallot shows prominent P waves in V1 (*) suggesting right atrial enlargement. There are also prominent right ventricular forces (tall R waves in V1), an upright T wave in V1, and a marked rightward axis suggesting right ventricular hypertrophy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Doyle, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_33_40470=[""].join("\n");
var outline_f39_33_40470=null;
var title_f39_33_40471="ECG in flash pulmonary edema";
var content_f39_33_40471=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Electrocardiogram in a patient with flash pulmonary edema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The ECG tracing reveals left ventricular hypertrophy (LVH) assoicated with ST segment depression and T wave inversions; these ST-T wave changes (arrows) may also represent subendocardial ischemia, which along with the LVH may be responsible for the episode of flash pulmonary edema.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_33_40471=[""].join("\n");
var outline_f39_33_40471=null;
var title_f39_33_40472="Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis";
var content_f39_33_40472=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/33/40472/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/33/40472/contributors\">",
"     Richard Lewis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/33/40472/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/33/40472/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/33/40472/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/33/40472/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/33/40472/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic inflammatory demyelinating polyneuropathy (CIDP, also known as chronic inflammatory demyelinating polyradiculoneuropathy) is an acquired disorder of peripheral nerves and nerve roots. There have been descriptions of patients with disorders that would now be considered CIDP for over 75 years, and the landmark report of Austin in 1958 described two patients with relapsing disease and glucocorticoid response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The concept of CIDP as a distinct entity was introduced in 1975 when a review of the clinical, electrodiagnostic, and pathologic findings of 53 patients was presented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/2\">",
"     2",
"    </a>",
"    ]. While that publication did not include \"demyelinating\" in the title, subsequent reports have included it, and demyelination is now recognized as a cardinal feature of the disorder.",
"   </p>",
"   <p>",
"    The classification, etiology, clinical features, and diagnosis of CIDP will be reviewed here. Treatment and prognosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17385?source=see_link\">",
"     \"Chronic inflammatory demyelinating polyneuropathy: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether CIDP is a disease or a syndrome remains controversial. The following neuropathies all have chronicity, demyelination, inflammation, or immune-mediation in common:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CIDP",
"     </li>",
"     <li>",
"      Multifocal motor neuropathy (MMN)",
"     </li>",
"     <li>",
"      Lewis-Sumner syndrome, also known as multifocal acquired demyelinating sensory and motor neuropathy (MADSAM)",
"     </li>",
"     <li>",
"      Distal demyelinating neuropathy with IgM paraprotein, with or without anti-myelin associated glycoprotein (anti-MAG)",
"     </li>",
"     <li>",
"      Demyelinating neuropathy with IgG or IgA paraprotein (the terms paraprotein and monoclonal gammopathy of undetermined significance [MGUS] are used synonymously in this setting)",
"     </li>",
"     <li>",
"      POEMS syndrome (osteosclerotic myeloma: polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/14/35049?source=see_link\">",
"       \"POEMS syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sensory predominant demyelinating neuropathy",
"     </li>",
"     <li>",
"      Demyelinating neuropathy with central nervous system demyelination",
"     </li>",
"     <li>",
"      Demyelinating neuropathy associated with systemic disorders, including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hepatitis B or C",
"     </li>",
"     <li>",
"      HIV infection",
"     </li>",
"     <li>",
"      Lymphoma",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Systemic lupus erythematosus or other collagen vascular disorders",
"     </li>",
"     <li>",
"      Thyrotoxicosis",
"     </li>",
"     <li>",
"      Organ or bone marrow transplants",
"     </li>",
"     <li>",
"      Inherited neuropathies",
"     </li>",
"     <li>",
"      Nephrotic syndrome",
"     </li>",
"     <li>",
"      Inflammatory bowel disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While there is no established consensus regarding the classification of all these neuropathies, there is general agreement that MMN, POEMS, and the MAG-related neuropathies are separate from CIDP and the other neuropathies on the basis of clinical, electrodiagnostic, and therapeutic distinctions.",
"   </p>",
"   <p>",
"    Most investigators consider the remaining disorders to be variants of CIDP since they have many clinical and electrodiagnostic features in common and treatment response with immunotherapy appears to be similar. The classification of inflammatory demyelinating neuropathies will continue to evolve as specific immune mechanisms are elucidated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Temporal continuum",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a temporal continuum between acute inflammatory demyelinating polyneuropathy (AIDP), the demyelinating form of Guillain-Barr&eacute; syndrome, and CIDP.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AIDP is a monophasic subacute illness that reaches its nadir within three to four weeks",
"     </li>",
"     <li>",
"      CIDP continues to progress or has relapses for greater than eight weeks",
"     </li>",
"     <li>",
"      Subacute inflammatory demyelinating polyneuropathy (SIDP) is the term used by some authors for disease that reaches its nadir between four and eight weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This arbitrary temporal delineation of inflammatory demyelinating polyneuropathy can occasionally be difficult to ascertain in practice. Only observation of the patient over time can clarify whether the clinical course is that of AIDP or CIDP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/5\">",
"     5",
"    </a>",
"    ], and therapeutic interventions are likely to be initiated before a patient reaches a specific time point that distinguishes between these entities. As an example, some patients with CIDP have a subacute onset resembling that seen in Guillain-Barr&eacute; syndrome, and CIDP is recognized only after relapses or progression occur over the ensuing few months.",
"   </p>",
"   <p>",
"    In addition to chronicity, other features may be useful to distinguish Guillain-Barr&eacute; syndrome (including AIDP) from CIDP.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The onset of Guillain-Barr&eacute; syndrome is usually easily identified, while the precise onset of CIDP is typically less clear. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/22/5481?source=see_link\">",
"       \"Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antecedent events are more frequent with Guillain-Barr&eacute; syndrome than in CIDP. Approximately 70 percent of AIDP cases are preceded by an infectious illness, vaccination, or surgery by three to four weeks prior to the onset of clinical symptoms. In contrast, most studies have found an antecedent event prior to CIDP in no more than 30 percent of patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40038?source=see_link&amp;anchor=H4#H4\">",
"       \"Pathogenesis of Guillain-Barr&eacute; syndrome in adults\", section on 'Antecedent events'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the cause of CIDP and its variants is unknown, there is evidence to support the hypotheses that the disorder(s) are immunologically based and have multiple triggers. Both the cellular and humoral components of the immune system appear to be involved in the pathogenesis of CIDP and its variants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cellular immunity involvement is supported by evidence of T-cell activation, crossing of the blood-nerve barrier by activated T-cells, and by expression of cytokines, tumor necrosis factor, interferons, and interleukins.",
"     </li>",
"     <li>",
"      Humoral immunity is implicated by the demonstration of immunoglobulin and complement deposition on myelinated nerve fibers, and by passive transfer experiments that induce conduction block and demyelination by injecting serum or purified IgG from CIDP patients into rats.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the immunologic cause(s) of CIDP remain unclear, since specific provoking antigens have not been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated prevalence of CIDP in populations from the UK, Australia, Italy, Japan, and the US is 0.8 to 8.9 per 100,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/9-14\">",
"     9-14",
"    </a>",
"    ]. CIDP can affect all ages but is more common in older males. It is thought that the disease is more likely to be progressive in the older age group and relapsing-remitting in younger patients.",
"   </p>",
"   <p>",
"    No specific predisposing factors for CIDP have been identified. There have been conflicting studies on human leukocyte antigen (HLA) type associations, but no clear genetic predisposition has been found. In several case reports, treatment with tumor necrosis factor-alpha inhibitors has been associated with the subsequent development of chronic demyelinating neuropathies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial description of CIDP in 1975 pointed out the major cardinal features of the disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/2\">",
"     2",
"    </a>",
"    ]. The classic form of CIDP is fairly symmetric and motor involvement is greater than sensory. Weakness is present in both proximal and distal muscles, and this pattern is a hallmark of acquired demyelinating polyneuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/5\">",
"     5",
"    </a>",
"    ]. Cranial nerve and bulbar involvement occur in 10 to 20 percent of patients.",
"   </p>",
"   <p>",
"    Most patients with CIDP also have sensory involvement and globally diminished or absent reflexes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/2,16\">",
"     2,16",
"    </a>",
"    ]. Sensory impairment in CIDP is usually greater for vibration and position sense than for pain and temperature sense, reflecting the involvement of larger myelinated fibers. Unlike the motor involvement, the sensory involvement tends to follow a distal to proximal gradient, although finger involvement is frequently seen as early as toe and foot involvement. Painful dysesthesias can occur in some patients. Back pain may also be present. Symptoms of lumbar spinal stenosis and cauda equina syndrome can occur rarely if there is marked nerve root hypertrophy, and may require surgical intervention.",
"   </p>",
"   <p>",
"    Autonomic involvement in CIDP is generally mild and limited in distribution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/17\">",
"     17",
"    </a>",
"    ]. Constipation and urinary retention are not usually early symptoms of CIDP, but may occur in more severe cases.",
"   </p>",
"   <p>",
"    Most patients with CIDP exhibit a slowly progressive course, but a relapsing-remitting course is noted in at least one-third, and may be more common in younger patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/16\">",
"     16",
"    </a>",
"    ]. The advent of early treatment for CIDP has made the temporal progression of the disease more difficult to characterize, since remissions may be related to therapy rather than to the natural course of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Variants of CIDP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical variants of CIDP are distinguished by their presentation and include the Lewis-Sumner syndrome, sensory-predominant CIDP, distal acquired demyelinating sensory neuropathy, and CIDP with central nervous system (CNS) involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Lewis-Sumner syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Lewis-Sumner syndrome, also known as multifocal acquired demyelinating sensory and motor neuropathy (MADSAM), presents with a much more striking multifocal picture, indistinguishable from other forms of mononeuropathy multiplex, with sensory",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    motor symptoms in individual nerve distributions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. A similar disorder of sensory ataxia due to inflammation confined to the dorsal roots known as chronic immune sensory polyradiculopathy or CISP may be a restricted form of CIDP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Sensory-predominant CIDP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sensory-predominant form of CIDP is characterized clinically by sensory symptoms and signs with balance problems, pain, paresthesias, and dysesthesias. Despite the lack of weakness, the nerve conduction studies demonstrate significant motor conduction slowing and other demyelinating features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Distal acquired demyelinating sensory neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal acquired demyelinating sensory neuropathy (DADS) is usually more slowly progressive than typical CIDP, and is frequently associated with an IgM paraprotein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/5,23\">",
"     5,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DADS with IgM paraprotein, whether or not associated with anti-MAG, is usually considered to be distinct from CIDP because it tends to be resistant to the standard immunomodulatory therapies for CIDP. Approximately one-half of patients with DADS and IgM paraprotein also have anti-MAG antibodies, but it is unclear whether presence or absence of these antibodies alters the clinical features of this disorder.",
"     </li>",
"     <li>",
"      DADS without IgM paraprotein is generally considered to be variant of CIDP because it may respond to treatment with immunomodulatory therapies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     CIDP with CNS involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;CIDP is occasionally associated with CNS involvement, including optic nerve disorders, hyperreflexia, Babinski signs, and MRI abnormalities of CNS demyelination. However, it is unclear whether these combined signs represent associated disease entities or coincidental occurrences of unrelated diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Electrophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral nerve demyelination underlies the characteristic electrophysiologic features of CIDP, which are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Partial conduction block",
"     </li>",
"     <li>",
"      Conduction velocity slowing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Prolonged distal motor latencies",
"     </li>",
"     <li>",
"      Delay or disappearance of F waves",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dispersion and distance dependent reduction of compound motor action potential (CMAP) amplitude",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic pathologic features of CIDP include segmental demyelination and remyelination, and onion bulb formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/2\">",
"     2",
"    </a>",
"    ]. The term &ldquo;onion-bulb formation\" refers to the appearance of affected nerves when viewed under the microscope in transverse section. As a result of repeated episodes of demyelination and remyelination, such nerves are enlarged due to whorls of overlapping and proliferating Schwann cell processes encircling bare axons. Some degree of axonal degeneration is usually present as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Varying degrees of interstitial edema and endoneurial inflammatory cell infiltrates, including lymphocytes and macrophages, are additional pathologic features of CIDP. The macrophages are thought to initiate the demyelination by unraveling and degrading the myelin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/26\">",
"     26",
"    </a>",
"    ]. Unfortunately, this is not commonly found on most biopsy specimens.",
"   </p>",
"   <p>",
"    While the exact mechanism of axonal degeneration in CIDP is not known, it has been considered to be a secondary bystander product of the inflammatory demyelinating process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of CIDP should be considered in patients with symmetric or asymmetric polyneuropathy who have a progressive or relapsing-remitting clinical course for more than two months, particularly if the clinical features include positive sensory symptoms, proximal weakness, areflexia without wasting, or selective loss of vibration or joint position sense [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the initial diagnosis of CIDP is clinical, the diagnosis is confirmed by evidence from electrodiagnostic studies, and in some cases by cerebrospinal fluid analysis, nerve biopsy findings, and other laboratory investigations. Peripheral nerve demyelination must be demonstrated by either electrodiagnostic findings or by nerve biopsy. A treatment trial may be indicated if the diagnosis remains unclear despite a thorough evaluation, since a positive response to immunotherapy may add supportive evidence to the diagnosis of CIDP. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17385?source=see_link\">",
"     \"Chronic inflammatory demyelinating polyneuropathy: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H572018605\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features that distinguish CIDP from chronic length-dependent (ie, axonal) peripheral neuropathies are the prominence of muscle weakness and the involvement of upper extremity and proximal muscles, as well as distal muscles. In contrast, axonal polyneuropathies are characterized by predominantly distal weakness. Furthermore, deep tendon reflexes are globally reduced or absent in CIDP, whereas only the ankle reflexes are diminished in typical axonal polyneuropathies. The features of CIDP point to the multifocal or generalized nature of the disease even at early stages of the illness.",
"   </p>",
"   <p>",
"    To confirm the diagnosis of CIDP, the clinician must be sure that the patient has a clinical picture that is consistent with the diagnosis and that the electrophysiology",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other studies (cerebrospinal fluid analysis, nerve biopsy, MRI) have features suggesting a demyelinating neuropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is general agreement that the following criteria support the diagnosis of the classic form of CIDP:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Progression over at least two months",
"     </li>",
"     <li>",
"      Weakness more than sensory symptoms",
"     </li>",
"     <li>",
"      Symmetric involvement of arms and legs",
"     </li>",
"     <li>",
"      Proximal muscles involved along with distal muscles",
"     </li>",
"     <li>",
"      Reduced deep tendon reflexes throughout",
"     </li>",
"     <li>",
"      Increased cerebrospinal fluid protein without pleocytosis",
"     </li>",
"     <li>",
"      Nerve conduction evidence of a demyelinating neuropathy",
"     </li>",
"     <li>",
"      Nerve biopsy evidence of segmental demyelination with or without inflammation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, there is still no gold standard set of diagnostic criteria for the electrophysiologic identification of demyelination, or for the clinical diagnosis of CIDP and its variants, even though multiple sets of diagnostic criteria have been published since 1989 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/5,27-33\">",
"     5,27-33",
"    </a>",
"    ]. Differences between these sets are related to definitions of the clinical picture, the requirements for nerve biopsy, electrodiagnostic criteria for demyelination, and the number of features required to make the diagnosis. The plethora of criteria sets for CIDP illustrate the difficulty of developing precise standards for problems that have multiple variations. Two sets of criteria &ndash; the Koski and the",
"    <span class=\"nowrap\">",
"     EFNS/PNS",
"    </span>",
"    &ndash; deserve special mention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239789\">",
"    <span class=\"h3\">",
"     Koski criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Koski criteria were derived by predictive modeling of the clinical data of 150 patients who were diagnosed by expert consensus as having CIDP or other polyneuropathies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/32\">",
"     32",
"    </a>",
"    ]. For the diagnosis of idiopathic CIDP, the Koski criteria require the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic polyneuropathy, progressive for at least eight weeks",
"     </li>",
"     <li>",
"      No serum paraprotein and no genetic abnormality and",
"      <br/>",
"      <strong>",
"       Either",
"      </strong>",
"     </li>",
"     <li>",
"      Recordable compound muscle action potentials in at least 75 percent of motor nerves and either abnormal distal latency or abnormal motor conduction velocity or abnormal F wave latency in &gt;50 percent of motor nerves",
"      <br/>",
"      <strong>",
"       Or",
"      </strong>",
"     </li>",
"     <li>",
"      Symmetric onset or symmetric exam and weakness in all four limbs and proximal weakness in at least one limb",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, while the Koski criteria combine clinical presentation and electrophysiologic abnormalities, either is sufficient to establish the diagnosis. One of the striking features of this classification method is that patients who have symmetric proximal and distal weakness are so likely to have CIDP that nerve conduction studies are primarily confirmatory. In an internal validation sample of 117 patients, the sensitivity and specificity of the Koski criteria were 83 percent (95% CI 69-93) and 97 percent (95% CI 89-99) respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239796\">",
"    <span class=\"h3\">",
"     EFNS/PNS criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the Koski classification is an interesting and valuable approach, we believe that the CIDP guideline from the European Federation of Neurological Societies and the Peripheral Nerve Society",
"    <span class=\"nowrap\">",
"     (EFNS/PNS),",
"    </span>",
"    published in 2006 and updated in 2010 (",
"    <a class=\"graphic graphic_table graphicRef71475 \" href=\"mobipreview.htm?33/40/34444\">",
"     table 1",
"    </a>",
"    ), is the one most useful for clinical practice and patient care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/27,33\">",
"     27,33",
"    </a>",
"    ]. When independently validated, the 2006 EFNS criteria had a sensitivity and specificity of 81 and 97 percent, whereas the Koski criteria had a sensitivity and specificity of 63 and 99 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/34\">",
"     34",
"    </a>",
"    ]. The lower sensitivity of the Koski criteria was primarily due problems detecting atypical cases of CIDP such as multifocal variants.",
"   </p>",
"   <p>",
"    Additional evidence supporting the utility of the",
"    <span class=\"nowrap\">",
"     EFNS/PNS",
"    </span>",
"    guideline comes from an earlier retrospective report that compared the performance of three proposed CIDP classification schemes &ndash; the American Academy of Neurology (AAN) criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/29\">",
"     29",
"    </a>",
"    ], the modified AAN criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/5\">",
"     5",
"    </a>",
"    ], and the 2006",
"    <span class=\"nowrap\">",
"     EFNS/PNS",
"    </span>",
"    criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/27\">",
"     27",
"    </a>",
"    ] &ndash; by applying them to data from 76 patients with symmetric neurologic deficits and electrophysiologic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    histologic evidence of peripheral nerve demyelination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/35\">",
"     35",
"    </a>",
"    ]. The sensitivities for the diagnosis of CIDP differed markedly for the AAN, modified AAN, and",
"    <span class=\"nowrap\">",
"     EFNS/PNS",
"    </span>",
"    criteria (0.52 versus 0.83 versus 0.95), while all three had similar specificities (0.94 versus 0.90 versus 0.96). Overall, the results favored use of the",
"    <span class=\"nowrap\">",
"     EFNS/PNS",
"    </span>",
"    criteria with respect to diagnosis.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     EFNS/PNS",
"    </span>",
"    guideline defines CIDP as typical (ie, classic) or atypical [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/33\">",
"     33",
"    </a>",
"    ]. Atypical CIDP encompasses variants of CIDP with predominantly distal weakness such as DADS, and variants with pure motor or pure sensory presentations. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Variants of CIDP'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     EFNS/PNS",
"    </span>",
"    diagnostic categories are determined by clinical, electrodiagnostic, and supportive criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/33\">",
"     33",
"    </a>",
"    ]. For definite CIDP, one must have a typical or atypical clinical picture with clear demyelinating electrodiagnostic changes in two nerves, or probable demyelinating features in two nerves plus at least one supportive feature (from cerebrospinal fluid analysis, nerve biopsy, MRI, or treatment response to immunotherapy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrodiagnostic testing is recommended for all patients with suspected CIDP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/27,33\">",
"     27,33",
"    </a>",
"    ]. Additional studies that may be indicated in select patients include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cerebrospinal fluid analysis",
"     </li>",
"     <li>",
"      Nerve biopsy",
"     </li>",
"     <li>",
"      MRI of spinal roots, brachial plexus, and lumbosacral plexus",
"     </li>",
"     <li>",
"      Laboratory studies",
"     </li>",
"     <li>",
"      Evaluation for inherited neuropathies",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Electrodiagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A critical component of the CIDP evaluation, electrodiagnostic testing is used to determine if there is demyelination, which causes reduced conduction velocity, prolonged distal motor latencies, dispersion and distance-dependent reduction of compound motor action potential (CMAP) amplitude [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/31\">",
"     31",
"    </a>",
"    ], and delay or disappearance of F waves.",
"   </p>",
"   <p>",
"    Most, but not all, patients with CIDP will have electrodiagnostic evidence of primary demyelination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/36\">",
"     36",
"    </a>",
"    ]. However, other focal or generalized nerve diseases (eg, diabetic neuropathy) can also result in slow conduction velocities or apparent block in neural conduction. As already mentioned, various sets of electrodiagnostic criteria for demyelinating neuropathy have been established to address this problem (",
"    <a class=\"graphic graphic_table graphicRef71475 \" href=\"mobipreview.htm?33/40/34444\">",
"     table 1",
"    </a>",
"    ). While these criteria can be helpful to the clinician, none have ideal sensitivity and specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extensive studies of the upper limbs or all four limbs, rather than unilateral or lower limb studies, may improve the electrodiagnostic yield [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Cerebrospinal fluid analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A lumbar puncture is supportive of the diagnosis of CIDP when the cerebrospinal fluid (CSF) protein is elevated and the CSF white cell count is normal (ie, the classic albuminocytologic dissociation). This finding is present in over 90 percent of patients with CIDP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/28\">",
"     28",
"    </a>",
"    ]. CSF protein elevations as high as 10 times the upper limits of normal are occasionally seen in patients with CIDP.",
"   </p>",
"   <p>",
"    An increased CSF white cell count of &gt;10",
"    <span class=\"nowrap\">",
"     cells/mm^3",
"    </span>",
"    should suggest a diagnosis other than CIDP. An exception to this general rule is that patients with HIV infection may have a cerebrospinal fluid pleocytosis, although the CSF white cell count in patients with CIDP and HIV infection is generally",
"    <span class=\"nowrap\">",
"     &lt;50/mm^3",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Nerve biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic utility of nerve biopsy (typically of the sural nerve) for suspected CIDP is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. Nerve biopsy is used mainly when other studies fail to clearly establish the diagnosis of CIDP, particularly when electrophysiologic criteria for demyelination are not met.",
"   </p>",
"   <p>",
"    A major limitation of nerve biopsy is suboptimal sensitivity and specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/27,33\">",
"     27,33",
"    </a>",
"    ]. CIDP is a multifocal disorder, and motor nerve fibers tend to be more affected than sensory nerves (the usual nerves used for biopsy). As a result, the biopsy sample may not demonstrate the demyelination. In addition, the inflammatory component of CIDP may not be prominent and thus may not be apparent on biopsy.",
"   </p>",
"   <p>",
"    Despite these drawbacks, nerve biopsy can provide solid evidence of demyelination. In addition, biopsy occasionally reveals other neuropathies that mimic CIDP, such as those due to amyloidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/41\">",
"     41",
"    </a>",
"    ], sarcoidosis, and vasculitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1530?source=see_link&amp;anchor=H14#H14\">",
"     \"An overview of amyloidosis\", section on 'Neurologic abnormalities'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/8/20616?source=see_link\">",
"     \"Neurologic sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22423?source=see_link\">",
"     \"Clinical manifestations of vasculitic neuropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16215?source=see_link\">",
"     \"Diagnosis and treatment of vasculitic neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The nerve selected for biopsy should be one that is clinically and electrophysiologically affected by the disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/33\">",
"     33",
"    </a>",
"    ]. However, care should be taken to choose a nerve that has either electrophysiologic or clinical evidence of functionality, as completely devastated nerves usually convey limited information. Typically, the sural nerve is biopsied, but other candidate nerves include the superficial peroneal, superficial radial, and gracilis motor nerve. Electron microscopy and teased fiber analysis of nerve biopsy specimens is highly desirable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Supportive features for CIDP on nerve biopsy include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Endoneurial edema",
"     </li>",
"     <li>",
"      Macrophage-associated demyelination",
"     </li>",
"     <li>",
"      Demyelinated and remyelinated nerve fibers",
"     </li>",
"     <li>",
"      Onion bulb formation (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Pathology'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Endoneurial mononuclear cell infiltration",
"     </li>",
"     <li>",
"      Variation between fascicles",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI with gadolinium of the spinal roots, cauda equina, brachial plexus, lumbosacral plexus, and other nerve regions can be used to look for enlarged or enhancing nerves. MRI abnormalities are useful as supportive criteria for CIDP in the",
"    <span class=\"nowrap\">",
"     EFNS/PNS",
"    </span>",
"    guideline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/33\">",
"     33",
"    </a>",
"    ]. The MRI results can also guide selection of abnormal nerves for biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no blood tests that specifically point to CIDP. However, a number of studies are useful to look for disorders that are either associated with or mimic CIDP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/33\">",
"     33",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fasting serum glucose",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      oral glucose tolerance test",
"     </li>",
"     <li>",
"      Glycated hemoglobin",
"     </li>",
"     <li>",
"      Thyroid function studies",
"     </li>",
"     <li>",
"      Hepatitis profiles",
"     </li>",
"     <li>",
"      HIV antibody",
"     </li>",
"     <li>",
"      Serum and urine immunofixation electrophoresis to detect paraprotein",
"     </li>",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      Renal function tests",
"     </li>",
"     <li>",
"      Liver function tests",
"     </li>",
"     <li>",
"      Borrelia burgdorferi serology",
"     </li>",
"     <li>",
"      C reactive protein",
"     </li>",
"     <li>",
"      Antinuclear antibodies",
"     </li>",
"     <li>",
"      Extractable nuclear antigen antibodies",
"     </li>",
"     <li>",
"      Angiotensin converting enzyme",
"     </li>",
"     <li>",
"      Chest radiograph",
"     </li>",
"     <li>",
"      Skeletal survey, if a paraprotein is found.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Genetic considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain genetic disorders of peripheral nerve myelin have characteristics that can mimic the clinical or electrodiagnostic features of CIDP or its variants. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hereditary neuropathy with liability to pressure palsies (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/24/21895?source=see_link&amp;anchor=H11#H11\">",
"       \"Overview of hereditary neuropathies\", section on 'Hereditary neuropathy with liability to pressure palsy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Charcot-Marie-Tooth (CMT) disease, particularly CMT1A, adult-onset CMT1B, and CMT1X (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/59/35770?source=see_link\">",
"       \"Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A careful family history and examination of parents and siblings is important if these disorders are a consideration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40472/abstract/33\">",
"     33",
"    </a>",
"    ]. Appropriate genetic testing should be considered in select patients, particularly for PMP22 gene duplication or deletion and connexin 32 mutations",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired disorder of peripheral nerves and nerve roots. Whether CIDP is a disease or a syndrome remains controversial. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a temporal continuum between acute inflammatory demyelinating polyneuropathy (AIDP), the demyelinating form of Guillain-Barr&eacute; syndrome, and CIDP. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Temporal continuum'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both the cellular and humoral components of the immune system appear to be involved in the pathogenesis of CIDP and its variants. However, the precise cause is unclear, since specific provoking antigens have not been identified. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The classic form of CIDP is fairly symmetric and motor involvement is greater than sensory. Weakness is present in both proximal and distal muscles. Most patients also have sensory involvement and globally diminished or absent reflexes. Sensory impairment in CIDP is usually greater for vibration and position sense than for pain and temperature sense. Cranial nerve and bulbar involvement occur in a minority. Most patients have a slowly progressive course, but a relapsing-remitting course is noted in at least one-third. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Major clinical variants of CIDP include (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Variants of CIDP'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Multifocal acquired demyelinating sensory and motor neuropathy (MADSAM), also known as Lewis-Sumner syndrome",
"     </li>",
"     <li>",
"      A sensory-predominant form of CIDP",
"     </li>",
"     <li>",
"      Distal acquired demyelinating sensory neuropathy (DADS)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The following criteria support the diagnosis of the classic form of CIDP (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnostic criteria'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Progression over at least two months",
"     </li>",
"     <li>",
"      Weakness more than sensory symptoms",
"     </li>",
"     <li>",
"      Symmetric involvement of arms and legs",
"     </li>",
"     <li>",
"      Proximal muscles involved along with distal muscles",
"     </li>",
"     <li>",
"      Reduced deep tendon reflexes throughout",
"     </li>",
"     <li>",
"      Increased cerebrospinal fluid protein without pleocytosis",
"     </li>",
"     <li>",
"      Nerve conduction evidence of a demyelinating neuropathy",
"     </li>",
"     <li>",
"      Nerve biopsy evidence of segmental demyelination with or without inflammation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While the initial diagnosis of CIDP is clinical, peripheral nerve demyelination must be demonstrated by either electrodiagnostic testing (",
"      <a class=\"graphic graphic_table graphicRef71475 \" href=\"mobipreview.htm?33/40/34444\">",
"       table 1",
"      </a>",
"      ) or by nerve biopsy. Electrodiagnostic testing is recommended for all patients with suspected CIDP. Additional investigations that are often indicated include (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cerebrospinal fluid analysis",
"     </li>",
"     <li>",
"      Nerve biopsy",
"     </li>",
"     <li>",
"      MRI of the spinal roots, brachial plexus, and lumbosacral plexus",
"     </li>",
"     <li>",
"      Laboratory studies to look for disorders that are either associated with or mimic CIDP",
"     </li>",
"     <li>",
"      Evaluation for inherited neuropathies",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/1\">",
"      AUSTIN JH. Recurrent polyneuropathies and their corticosteroid treatment; with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone, and prednisone. Brain 1958; 81:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/2\">",
"      Dyck PJ, Lais AC, Ohta M, et al. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975; 50:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/3\">",
"      Hughes R, Sanders E, Hall S, et al. Subacute idiopathic demyelinating polyradiculoneuropathy. Arch Neurol 1992; 49:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/4\">",
"      Oh SJ, Kurokawa K, de Almeida DF, et al. Subacute inflammatory demyelinating polyneuropathy. Neurology 2003; 61:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/5\">",
"      Saperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001; 24:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/6\">",
"      Dalakas MC, Medscape. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol 2011; 7:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/7\">",
"      Schneider-Hohendorf T, Schwab N, U&ccedil;eyler N, et al. CD8+ T-cell immunity in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2012; 78:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/8\">",
"      Peltier AC, Donofrio PD. Chronic inflammatory demyelinating polyradiculoneuropathy: from bench to bedside. Semin Neurol 2012; 32:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/9\">",
"      Lunn MP, Manji H, Choudhary PP, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry 1999; 66:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/10\">",
"      McLeod JG, Pollard JD, Macaskill P, et al. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 1999; 46:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/11\">",
"      Chi&ograve; A, Cocito D, Bottacchi E, et al. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry 2007; 78:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/12\">",
"      Iijima M, Koike H, Hattori N, et al. Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J Neurol Neurosurg Psychiatry 2008; 79:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/13\">",
"      Rajabally YA, Simpson BS, Beri S, et al. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve 2009; 39:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/14\">",
"      Laughlin RS, Dyck PJ, Melton LJ 3rd, et al. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 2009; 73:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/15\">",
"      Lozeron P, Denier C, Lacroix C, Adams D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 2009; 66:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/16\">",
"      McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 1987; 110 ( Pt 6):1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/17\">",
"      Figueroa JJ, Dyck PJ, Laughlin RS, et al. Autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2012; 78:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/18\">",
"      Lewis RA, Sumner AJ, Brown MJ, Asbury AK. Multifocal demyelinating neuropathy with persistent conduction block. Neurology 1982; 32:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/19\">",
"      Rajabally YA, Chavada G. Lewis-sumner syndrome of pure upper-limb onset: diagnostic, prognostic, and therapeutic features. Muscle Nerve 2009; 39:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/20\">",
"      Sinnreich M, Klein CJ, Daube JR, et al. Chronic immune sensory polyradiculopathy: a possibly treatable sensory ataxia. Neurology 2004; 63:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/21\">",
"      Trip SA, Saifee T, Honan W, et al. Chronic immune sensory polyradiculopathy with cranial and peripheral nerve involvement. J Neurol 2012; 259:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/22\">",
"      Oh SJ, Joy JL, Kuruoglu R. \"Chronic sensory demyelinating neuropathy\": chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry 1992; 55:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/23\">",
"      Katz JS, Saperstein DS, Gronseth G, et al. Distal acquired demyelinating symmetric neuropathy. Neurology 2000; 54:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/24\">",
"      Feasby TE, Hahn AF, Koopman WJ, Lee DH. Central lesions in chronic inflammatory demyelinating polyneuropathy: an MRI study. Neurology 1990; 40:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/25\">",
"      Harbo T, Andersen H, Jakobsen J. Length-dependent weakness and electrophysiological signs of secondary axonal loss in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2008; 38:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/26\">",
"      Prineas JW. Demyelination and remyelination in recurrent idiopathic polyneuropathy. An electron microscope study. Acta Neuropathol 1971; 18:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/27\">",
"      Hughes RA, Bouche P, Cornblath DR, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006; 13:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/28\">",
"      Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989; 46:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/29\">",
"      Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991; 41:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/30\">",
"      Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/31\">",
"      Thaisetthawatkul P, Logigian EL, Herrmann DN. Dispersion of the distal compound muscle action potential as a diagnostic criterion for chronic inflammatory demyelinating polyneuropathy. Neurology 2002; 59:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/32\">",
"      Koski CL, Baumgarten M, Magder LS, et al. Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2009; 277:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/33\">",
"      Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society--First Revision. J Peripher Nerv Syst 2010; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/34\">",
"      Rajabally YA, Nicolas G, Pi&eacute;ret F, et al. Validity of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy: a multicentre European study. J Neurol Neurosurg Psychiatry 2009; 80:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/35\">",
"      Tackenberg B, L&uuml;nemann JD, Steinbrecher A, et al. Classifications and treatment responses in chronic immune-mediated demyelinating polyneuropathy. Neurology 2007; 68:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/36\">",
"      Van den Bergh PY, Pi&eacute;ret F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2004; 29:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/37\">",
"      Rajabally YA, Jacob S, Hbahbih M. Optimizing the use of electrophysiology in the diagnosis of chronic inflammatory demyelinating polyneuropathy: a study of 20 cases. J Peripher Nerv Syst 2005; 10:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/38\">",
"      Molenaar DS, Vermeulen M, de Haan R. Diagnostic value of sural nerve biopsy in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 1998; 64:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/39\">",
"      Bosboom WM, van den Berg LH, Franssen H, et al. Diagnostic value of sural nerve demyelination in chronic inflammatory demyelinating polyneuropathy. Brain 2001; 124:2427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/40\">",
"      Vallat JM, Tabaraud F, Magy L, et al. Diagnostic value of nerve biopsy for atypical chronic inflammatory demyelinating polyneuropathy: evaluation of eight cases. Muscle Nerve 2003; 27:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40472/abstract/41\">",
"      Mathis S, Magy L, Diallo L, et al. Amyloid neuropathy mimicking chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2012; 45:26.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5264 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-071942397F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_33_40472=[""].join("\n");
var outline_f39_33_40472=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Temporal continuum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Variants of CIDP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Lewis-Sumner syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Sensory-predominant CIDP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Distal acquired demyelinating sensory neuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - CIDP with CNS involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Electrophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H572018605\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1239789\">",
"      - Koski criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1239796\">",
"      - EFNS/PNS criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Electrodiagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Cerebrospinal fluid analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Nerve biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - MRI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Genetic considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5264\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5264|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/40/34444\" title=\"table 1\">",
"      Electrodiagnostic criteria CIDP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1530?source=related_link\">",
"      An overview of amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17385?source=related_link\">",
"      Chronic inflammatory demyelinating polyneuropathy: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/22/5481?source=related_link\">",
"      Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22423?source=related_link\">",
"      Clinical manifestations of vasculitic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16215?source=related_link\">",
"      Diagnosis and treatment of vasculitic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/59/35770?source=related_link\">",
"      Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/8/20616?source=related_link\">",
"      Neurologic sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/24/21895?source=related_link\">",
"      Overview of hereditary neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/14/35049?source=related_link\">",
"      POEMS syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40038?source=related_link\">",
"      Pathogenesis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_33_40473="An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women";
var content_f39_33_40473=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/33/40473/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/33/40473/contributors\">",
"     Rebecca G Rogers, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/33/40473/contributors\">",
"     Tola B Fashokun, MD, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/33/40473/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/33/40473/contributors\">",
"     Linda Brubaker, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/33/40473/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/33/40473/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/33/40473/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H21524713\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic organ prolapse (POP), the herniation of the pelvic organs to or beyond the vaginal walls, is a common condition. Many women with prolapse experience symptoms that impact daily activities, sexual function, and exercise. The presence of POP can have a detrimental impact on body image and sexuality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/1\">",
"     1",
"    </a>",
"    ]. Treatment of POP requires significant health care resources; the annual cost of ambulatory care of pelvic floor disorders in the United States from 2005 to 2006 was almost $300 million [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/2\">",
"     2",
"    </a>",
"    ] and surgical repair of prolapse was the most common inpatient procedure performed in women older than 70 years from 1979 to 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/3\">",
"     3",
"    </a>",
"    ]. The health care impact of prolapse is likely to expand, based upon estimates of an increasing prevalence in the growing population of elderly women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, risk factors, clinical manifestations, and general principles of management are reviewed here. Management of prolapse with vaginal pessaries and choosing a primary surgical procedure for prolapse repair are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/7/17530?source=see_link\">",
"     \"Vaginal pessary treatment of prolapse and incontinence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9337?source=see_link\">",
"     \"Pelvic organ prolapse in women: Choosing a primary surgical procedure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7156411\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pelvic organ prolapse (POP) &ndash; The herniation of the pelvic organs to or beyond the vaginal walls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Commonly used terms to describe specific sites of female genital prolapse include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anterior compartment prolapse &ndash; Hernia of anterior vaginal wall often associated with descent of the bladder (cystocele) (",
"      <a class=\"graphic graphic_figure graphicRef62745 \" href=\"mobipreview.htm?14/63/15349\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Posterior compartment prolapse &ndash; Hernia of the posterior vaginal segment often associated with descent of the rectum (rectocele) (",
"      <a class=\"graphic graphic_picture graphicRef51685 \" href=\"mobipreview.htm?38/19/39218\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Enterocele &ndash; Hernia of the intestines to or through the vaginal wall.",
"     </li>",
"     <li>",
"      Apical compartment prolapse (uterine prolapse, vaginal vault prolapse) &ndash; Descent of the apex of the vagina into the lower vagina, to the hymen, or beyond the vaginal introitus (",
"      <a class=\"graphic graphic_picture graphicRef64451 \" href=\"mobipreview.htm?29/39/30322\">",
"       picture 2",
"      </a>",
"      ). The apex can be either the uterus and cervix, cervix alone, or vaginal vault, depending upon whether the woman has undergone hysterectomy. Apical prolapse is often associated with enterocele.",
"     </li>",
"     <li>",
"      Uterine procidentia &mdash; Hernia of all three compartments through the vaginal introitus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The terms anterior vaginal wall prolapse and posterior vaginal wall prolapse are preferred to cystocele and rectocele because vaginal topography does not reliably predict the location of the associated viscera in POP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Division of the vagina into separate compartments is somewhat arbitrary, because the vagina is a continuous organ and prolapse of one compartment is often associated with prolapse of another. As an example, approximately half of anterior prolapse can be attributed to apical descent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H690213\">",
"    <span class=\"h1\">",
"     ANATOMY OF PELVIC SUPPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anatomic support of the pelvic organs in women is provided by an interaction between the muscles of the pelvic floor and connective tissue attachments to the bony pelvis (",
"    <a class=\"graphic graphic_figure graphicRef60078 \" href=\"mobipreview.htm?33/45/34513\">",
"     figure 2",
"    </a>",
"    ). The levator ani muscle complex, consisting of the pubococcygeus, puborectalis and iliococcygeus muscles, provides primary support to the pelvic organs, providing a firm, yet elastic-base upon which the pelvic organs rest (",
"    <a class=\"graphic graphic_figure graphicRef82007 \" href=\"mobipreview.htm?25/8/25736\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef51329 \" href=\"mobipreview.htm?6/27/6586\">",
"     figure 4",
"    </a>",
"    ). The endopelvic fascial attachments, in particular condensations of the endopelvic fascia referred to as the uterosacral and cardinal ligaments, stabilize the pelvic organs in the correct position so that the pelvic muscles can provide optimal support (",
"    <a class=\"graphic graphic_figure graphicRef57811 \" href=\"mobipreview.htm?5/56/6026\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H690220\">",
"    <span class=\"h2\">",
"     Levels of pelvic organ support",
"    </span>",
"    &nbsp;&mdash;&nbsp;A system of three integrated levels of vaginal support has been described by DeLancey (",
"    <a class=\"graphic graphic_figure graphicRef61643 \" href=\"mobipreview.htm?26/4/26693\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Level 1 &ndash;",
"      <span class=\"nowrap\">",
"       Uterosacral/cardinal",
"      </span>",
"      ligament complex, which suspends the uterus and upper vagina to the sacrum and lateral pelvic side wall. Loss of level 1 support contributes to the prolapse of the uterus",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vaginal apex. &nbsp;",
"     </li>",
"     <li>",
"      Level 2 &ndash; Paravaginal attachments along the length of the vagina to the superior fascia of the levator ani muscle and the arcus tendineus fascia pelvis (also referred to as the &ldquo;white line&rdquo;). Loss of level 2 support contributes to anterior vaginal wall prolapse (cystocele).",
"     </li>",
"     <li>",
"      Level 3 &ndash; Perineal body, perineal membrane, and superficial and deep perineal muscles, which support the distal one third of the vagina. Anteriorly, loss of level 3 support can result in urethral hypermobility. Posteriorly, loss of level 3 support can result in a distal rectocele or perineal descent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All levels of support are connected through a continuous supporting network of endopelvic fascia. Defects in this network can occur at one level or at all levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691664\">",
"    <span class=\"h2\">",
"     Nerve supply",
"    </span>",
"    &nbsp;&mdash;&nbsp;The innervation of the pelvic region derives from the S2, S3, and S4 segments of the spinal cord, which fuse to form the pudendal nerve. The pudendal nerve innervates the external anal sphincter, whereas the levators, coccygeus muscles, and urogenital diaphragm appear to be innervated by a direct connection of S2, S3, and S4 nerve fibers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21524720\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact prevalence of POP is difficult to ascertain, for several reasons: (1) different classification systems have been used for diagnosis (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/46/8937?source=see_link&amp;anchor=H1120849#H1120849\">",
"     \"Pelvic organ prolapse in women: Diagnostic evaluation\", section on 'Classification of pelvic organ prolapse'",
"    </a>",
"    .); (2) studies vary by whether the rate of prolapse reported is for women who are symptomatic or asymptomatic; and (3) it is unknown how many women with POP do not seek medical attention.",
"   </p>",
"   <p>",
"    The distinction between symptomatic and asymptomatic POP is clinically relevant, since treatment is generally indicated only for women with symptoms. However, there are few high quality data regarding the prevalence of symptomatic POP. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9337?source=see_link&amp;anchor=H10284328#H10284328\">",
"     \"Pelvic organ prolapse in women: Choosing a primary surgical procedure\", section on 'Women with symptomatic prolapse'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a cross-sectional study, the United States (US) National Health and Nutrition Examination Survey (NHANES), 1961 women aged 20 to 80 years were interviewed. The authors defined symptomatic prolapse as a positive response to the question, \"do you experience bulging or something falling out you can see or feel in the vaginal area?\" and reported a 2.9 percent prevalence of symptomatic POP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/12\">",
"     12",
"    </a>",
"    ]. The question used in this study was derived from the Pelvic Floor Distress Inventory; a positive response correlates with the presence of a vaginal bulge on examination. However, the question has higher specificity than sensitivity for POP based on examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/13\">",
"     13",
"    </a>",
"    ]. Population based surveys have found that 6 to 8 percent of women report symptoms of POP; no physical examination to assess prolapse was performed in these studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Prolapse estimates using only questionnaires underreport the true prevalence of prolapse based on clinical examination.",
"   </p>",
"   <p>",
"    A higher prevalence of symptomatic POP is suggested by the number of women who undergo surgical prolapse repair. Approximately 200,000 inpatient surgical procedures for prolapse are performed annually in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Population based studies report an 11 to 19 percent lifetime risk in women undergoing surgery for prolapse or incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. These data likely underestimate the number of women with symptomatic POP, since many women do not undergo surgery.",
"   </p>",
"   <p>",
"    Rates of asymptomatic POP are probably even higher. Several studies have used clinical examination to assess the prevalence of POP in a community-based setting. One study included 497 women who were seen in an outpatient clinic for routine gynecologic care and were assessed using the Pelvic Organ Prolapse Quantitation (POP-Q) system. The overall distribution of POP-Q system stages was as follows: stage 0, 6.4 percent; stage 1, 43.3 percent; stage 2, 47.7 percent; and stage 3, 2.6 percent. No subjects examined had POP-Q system stage 4 prolapse. The distribution of the POP-Q system stages in the population revealed a bell-shaped curve, with most subjects having stage 1 or 2 support. Few subjects had either stage 0 (excellent support) or stage 3 (moderate to severe pelvic support defects) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Women&rsquo;s Health Initiative study, which used a non-validated physical examination to assess pelvic organ support in postmenopausal women, the overall rates for prolapse in this population were 41 percent for women with a uterus and 38 percent posthysterectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/21\">",
"     21",
"    </a>",
"    ]. Anterior vaginal wall defects (33 to 34 percent) were significantly more common than posterior wall (18 percent) or apical defects (14 percent); it is important to note that the vagina is a continuous organ and defects in the apex contribute to anterior and posterior vaginal wall prolapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/7\">",
"     7",
"    </a>",
"    ]. This study, however, did not assess women who had undergone previous surgeries other than hysterectomy and so women who have undergone prolapse surgery may have been included in this study population.",
"   </p>",
"   <p>",
"    In another study of younger women, the total rate of prolapse on pelvic examination in women was 31 percent, with only 1.6 percent of women with prolapse to the hymen and none beyond the hymen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21524727\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Established risk factors for POP include parity, advancing age, and obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/18/19753?source=see_link\">",
"     \"Pelvic floor disorders associated with pregnancy and childbirth\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691443\">",
"    <span class=\"h2\">",
"     Parity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of POP increases with increasing parity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/12,24,25\">",
"     12,24,25",
"    </a>",
"    ]. As an example, the Oxford Family Planning study, a prospective cohort study of more than 17,000 women followed for 17 years found that, compared with nulliparity, the risk of hospital admission for POP increased markedly after the first (4-fold) and second birth (8-fold), and then increased less rapidly for subsequent births (third: 9-fold; fourth: 10-fold) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/25\">",
"     25",
"    </a>",
"    ]. Among parous women, it has been estimated that 75 percent of prolapse can be attributed to pregnancy and childbirth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Obstetric factors in addition to parity can influence the risk of prolapse. POP can develop during pregnancy prior to delivery. Vaginal delivery is associated with a higher incidence of POP than cesarean. A detailed discussion of the effects of pregnancy and childbirth on POP can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/18/19753?source=see_link&amp;anchor=H2#H2\">",
"     \"Pelvic floor disorders associated with pregnancy and childbirth\", section on 'Association of PFD with pregnancy and childbirth'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691457\">",
"    <span class=\"h2\">",
"     Advancing age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older women are at an increased risk for POP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/27\">",
"     27",
"    </a>",
"    ]. A progressive increase in the rate of prolapse with age was reported in one study among 1000 women presenting for an annual gynecological exam; every additional 10 years of age conferred an increased risk of prolapse of 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/28\">",
"     28",
"    </a>",
"    ]. In contrast, in the NHANES study described above, the proportion of women with symptomatic prolapse was lowest in young women and then remained fairly constant over age 40 years: ages 20 to 39 (1.6 percent); 40 to 59 (3.8 percent); 60 to 79 (3.0 percent); and &ge;80 (4.1 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691464\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overweight and obese women (body mass index &gt;25) have a two-fold higher risk of having prolapse than other women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/28\">",
"     28",
"    </a>",
"    ]. While weight gain is a risk factor for developing prolapse, it is controversial whether weight loss results in prolapse regression. A study of 16,608 postmenopausal women found no association with weight loss and regression of POP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/29\">",
"     29",
"    </a>",
"    ]. However, there are reports of POP regression in women after bariatric surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691472\">",
"    <span class=\"h2\">",
"     Hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysterectomy is associated with an increased risk of apical prolapse. Factors that may influence the risk of prolapse after hysterectomy are age and the surgical route (abdominal or vaginal). A detailed discussion of the risk of prolapse after hysterectomy can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/19/12602?source=see_link&amp;anchor=H22#H22\">",
"     \"Overview of hysterectomy\", section on 'Pelvic organ prolapse'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7156775\">",
"    <span class=\"h2\">",
"     Race and ethnicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data suggest that African-American women have a lower prevalence of symptomatic POP than other racial or ethnic groups in the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/15,21,31\">",
"     15,21,31",
"    </a>",
"    ]. In a prospective cohort study of 2270 women, the risk in Latina and white women was four- to five-fold higher than in African-American women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/31\">",
"     31",
"    </a>",
"    ]. In contrast, other studies have found no relationship between POP and race or ethnicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/12,32\">",
"     12,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1841428\">",
"    <span class=\"h2\">",
"     Other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic constipation is a risk factor for POP, likely due to repetitive increases in intraabdominal pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Data conflict regarding whether the risk of prolapse is increased in women with occupations that involve heavy lifting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/28,35\">",
"     28,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some connective tissue disorders (eg, Ehlers-Danlos syndrome) or congenital abnormalities (eg, bladder exstrophy) contribute to POP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of 16 studies found a 2.5-fold increased risk of prolapse in women with a family history of the condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/39\">",
"     39",
"    </a>",
"    ]. There are few data regarding a genetic component of prolapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8625211\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolapse prevention strategies have not been extensively studied. Although vaginal childbirth is associated with an increased risk of prolapse, it is unclear that cesarean delivery will prevent the occurrence of prolapse. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/18/19753?source=see_link&amp;anchor=H10#H10\">",
"     \"Pelvic floor disorders associated with pregnancy and childbirth\", section on 'Can obstetrical care be modified to reduce pfd?'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prevention of progression of prolapse has not been well studied. Some data suggest that women with prolapse who use a vaginal pessary have a lower stage of prolapse on subsequent exams [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/42\">",
"     42",
"    </a>",
"    ]. Interventions such as weight loss, treatment of chronic constipation, and avoidance of jobs that require heavy lifting are potential interventions to avoid the development or progression of POP and deserve further investigation.",
"   </p>",
"   <p>",
"    A systematic review of six randomized trials evaluated the effects of estrogens or medications with estrogenic effects (eg, selective estrogen receptor modulators), either alone or in conjunction with other treatments, for prevention of POP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/43\">",
"     43",
"    </a>",
"    ]. Regarding prevention, the only finding with sufficient data for meta-analysis was that use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    in women who were 60 years or older resulted in a significant reduction in the proportion of women who subsequently underwent surgery (0.8 versus 1.5 percent; OR 0.5, 95% CI 0.3-0.8); no significant association between raloxifene and surgery was found in women who were less than 60 years. Further study is needed of the role of estrogenic agents in the prevention of POP. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21524755\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with POP may present with symptoms related specifically to the prolapsed structures, such as a bulge or vaginal pressure or with associated symptoms including urinary, defecatory or sexual dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/23\">",
"     23",
"    </a>",
"    ]. Symptoms such as low back or pelvic pain have often been attributed to POP, but this association is not supported by well-designed studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severity of symptoms does not correlate well with the stage of prolapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/28,46-50\">",
"     28,46-50",
"    </a>",
"    ]. Symptoms are often related to position; they are often less noticeable in the morning or while supine and worsen as the day progresses.",
"   </p>",
"   <p>",
"    Many women with prolapse are asymptomatic; treatment is generally not indicated in these women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9337?source=see_link&amp;anchor=H10284328#H10284328\">",
"     \"Pelvic organ prolapse in women: Choosing a primary surgical procedure\", section on 'Women with symptomatic prolapse'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1842335\">",
"    <span class=\"h2\">",
"     Bulge or pressure symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with POP often present with the complaint of vaginal or pelvic pressure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the sensation of a vaginal bulge or something falling out of the vagina.",
"   </p>",
"   <p>",
"    In a study of 1912 women presenting to a pelvic floor disorder clinic, symptoms of &ldquo;a bulge or that something is falling out of the vagina&rdquo; had a sensitivity of 67 percent and a specificity of 87 percent for POP at or past the hymen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/51\">",
"     51",
"    </a>",
"    ]. Although complaints of a bulge are associated with the presence of prolapse, it is only weakly correlated with prolapse stage, and does not predict site of prolapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The anatomic threshold for symptomatic prolapse appears to be the hymen. The specificity of vaginal bulge symptoms for predicting prolapse beyond the hymen is high (99 percent to 100 percent); however, the sensitivity is low (16 percent to 35 percent) because even some women with advanced prolapse report an absence of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. A cross-sectional study of women older than 40 years undergoing gynecologic and urogynecologic examinations using POP-Q examinations to assess support and Pelvic Floor Distress Inventory questionnaires to assess symptoms determined that the anatomic threshold of 0.5 cm distal to the hymen had sensitivity (69 percent) and specificity (97 percent) for",
"    <span class=\"nowrap\">",
"     protrusion/bulge",
"    </span>",
"    symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some women are able to see a protrusion of the prolapse beyond the introitus (",
"    <a class=\"graphic graphic_picture graphicRef70607 \" href=\"mobipreview.htm?19/54/20320\">",
"     picture 3",
"    </a>",
"    ). Protrusion of the vagina may result in chronic discharge",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bleeding from ulceration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24639614\">",
"    <span class=\"h2\">",
"     Urinary symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of support of the anterior vaginal wall or vaginal apex may affect bladder",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urethral function. Symptoms of stress urinary incontinence (SUI) often coexist with stage I or II prolapse",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/46,54\">",
"     46,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As prolapse advances, women may experience improvement in SUI, but increased difficulty voiding. Advanced anterior or apical prolapse, the prolapse may &ldquo;kink&rdquo; the urethra, thereby resulting in symptoms of obstructed voiding, such as a slow urine stream, the need to change position or manually reduce (splint) the prolapse to urinate, a sensation of incomplete emptying and, in rare cases, complete urinary retention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/23\">",
"     23",
"    </a>",
"    ]. The correlation of obstructive symptoms with advancing prolapse was illustrated in the study of women presenting to a pelvic floor clinic described above, in which urinary splinting was reported by 5 to 12 percent of women with stage II anterior prolapse and 23 to 36 percent of those with stage III or IV anterior prolapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1842335\">",
"     'Bulge or pressure symptoms'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Thirteen to 65 percent of continent women develop symptoms of SUI after surgical correction of prolapse. Elevation of prolapse during pelvic examination with prolapse treatment may unmask &ldquo;occult&rdquo; SUI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/32/1546?source=see_link&amp;anchor=H15#H15\">",
"     \"Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment\", section on 'POP with no symptoms of SUI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with POP have a two- to five-fold risk of overactive bladder symptoms (urgency, urge urinary incontinence, frequency) compared with the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Data are mixed regarding whether the anatomic site (apical, anterior, posterior) and severity of prolapse correlate with the presence of such symptoms.",
"   </p>",
"   <p>",
"    In addition, some women with POP experience enuresis or incontinence with sexual intercourse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/57-59\">",
"     57-59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21524762\">",
"    <span class=\"h2\">",
"     Defecatory symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common bowel symptom associated with prolapse is constipation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/46,48\">",
"     46,48",
"    </a>",
"    ]. Other defecatory symptoms include fecal urgency and fecal incontinence and obstructive symptoms, eg, incomplete emptying, straining, or the need to apply digital pressure to the vagina or perineum (splint) to completely evacuate; some women report fecal incontinence during sexual intercourse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/23,59\">",
"     23,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Defecatory symptoms may be present in women with any anatomic site of prolapse, although they tend to be found more commonly associated with posterior or apical defects",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/33,46\">",
"     33,46",
"    </a>",
"    ]. In the study of women presenting to a pelvic floor clinic described above, women with stage I prolapse were the least likely to require splinting to defecate (8 to 15 percent), but the likelihood of splinting symptoms did not continue to increase with advancing prolapse (stage II: 21 to 38 percent; stage III to IV: 26 to 29 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1842335\">",
"     'Bulge or pressure symptoms'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24639741\">",
"    <span class=\"h2\">",
"     Effects on sexual function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolapse does not appear to be associated with decreased sexual desire or with dyspareunia, although reports vary according to whether POP is associated with adverse effects on orgasm or sexual satisfaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Some women report that they avoid sexual activity because of fear of discomfort or embarrassment associated with POP, particularly those with urinary or fecal incontinence during sexual activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7156639\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;POP is diagnosed using pelvic examination. A medical history is also important to elicit prolapse-associated symptoms, since treatment is generally indicated only for symptomatic prolapse. Since its introduction in 1996 and adoption by the Society of Gynecologic Surgeons, American Urogynecologic Society, and International Continence Society, the Pelvic Organ Prolapse Quantitation (POPQ) system has become the most commonly used prolapse staging system.",
"   </p>",
"   <p>",
"    A detailed discussion of the diagnosis and classification of prolapse can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/46/8937?source=see_link\">",
"     \"Pelvic organ prolapse in women: Diagnostic evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8625139\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolapse has traditionally been regarded as a progressive disease, with mild prolapse inexorably leading to more advanced disease. However, data suggest that the course is progressive until menopause, after which the degree of prolapse may follow a course of alternating progression and regression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. Prolapse regression was demonstrated in a prospective cohort study of 249 women who were followed over a three-year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/63\">",
"     63",
"    </a>",
"    ]. Prolapse increased by at least 2 cm in 11 percent of women and regressed by the same amount in 3 percent of women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7157266\">",
"    <span class=\"h1\">",
"     APPROACH TO MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13817287\">",
"    <span class=\"h2\">",
"     Indications for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is indicated for women with symptoms of prolapse or associated conditions (urinary, bowel, or sexual dysfunction). Obstructed urination or defecation or hydronephrosis from chronic ureteral kinking are all indications for treatment, regardless of degree of prolapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/23\">",
"     23",
"    </a>",
"    ]. Treatment is generally not indicated for women with asymptomatic prolapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7157274\">",
"    <span class=\"h2\">",
"     Establishing patient goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is individualized according to each patient&rsquo;s symptoms and their impact on her quality of life. Studies have demonstrated that patient satisfaction after pelvic reconstructive surgery correlates highly with achievement of self-described, preoperative surgical goals, but poorly with objective outcome measures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/66-68\">",
"     66-68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13817294\">",
"    <span class=\"h2\">",
"     Management options",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with symptomatic prolapse can be managed expectantly, or treated with conservative or surgical therapy. Both conservative and surgical treatment options should be offered. There are no high quality data comparing these two approaches.",
"   </p>",
"   <p>",
"    The choice of therapy depends upon the patient&rsquo;s preferences, as well as the ability to comply with conservative therapy or tolerate surgery. Some data suggest that age, the degree of POP as measured by descent of leading edge of prolapse, preoperative pelvic pain scores, and prior prolapse surgery are independently associated with treatment choices. In a study of 152 women, older patients and those with increased preoperative pelvic pain scores were more likely to choose pessary over surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/45\">",
"     45",
"    </a>",
"    ]. On the other hand, the likelihood of choosing surgery was increased in women with more severe prolapse or a prior POP repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7157464\">",
"    <span class=\"h3\">",
"     Expectant management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expectant management is a viable option for women who can tolerate their symptoms and prefer to avoid treatment.",
"   </p>",
"   <p>",
"    Women with symptomatic or asymptomatic prolapse who decline treatment, particularly stage III or IV, should be evaluated on a regular basis to assess for the development or worsening of urinary or defecatory symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8624710\">",
"    <span class=\"h3\">",
"     Conservative management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conservative therapy is the first line option for all women with POP, since surgical treatment incurs the risk of complications and recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/69\">",
"     69",
"    </a>",
"    ]. However, prolapse is typically a chronic problem, and many women ultimately prefer surgery to conservative therapy since successful surgery does not require ongoing maintenance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8624733\">",
"    <span class=\"h4\">",
"     Vaginal pessary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of",
"    <strong>",
"    </strong>",
"    non-surgical treatment for POP is the vaginal pessary. Pessaries are silicone devices in a variety of shapes and sizes, which support the pelvic organs. Approximately half of the women who use a pessary continue to do so in the intermediate term of one to two years. Pessaries must be removed and cleaned on a regular basis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/7/17530?source=see_link\">",
"     \"Vaginal pessary treatment of prolapse and incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8624747\">",
"    <span class=\"h4\">",
"     Pelvic floor muscle exercises",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic floor muscle exercises (PFME) appear to result in improvements in POP stage and POP-associated symptoms. Several randomized trials have investigated this issue, although most have been small or were of poor methodologic quality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/70\">",
"     70",
"    </a>",
"    ]. The best designed randomized trial included 109 women with stage I to III prolapse who were assigned to either PFME for six months with regular supervision by a physical therapist or to a control group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/71\">",
"     71",
"    </a>",
"    ]. Women in the PFME group had significant reductions in the frequency and bother of most prolapse, bladder, and bowel symptoms (exceptions were urge urinary incontinence symptoms, difficulty with stool emptying, and solid stool fecal incontinence). Improvement in POP stage was found more frequently in the PFME group (19 versus 8 percent). Further study is needed of the effect of PFME on POP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6514468\">",
"    <span class=\"h4\">",
"     Estrogen therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data about the use of estrogen therapy for treatment of symptomatic POP. Use of estrogenic agents (in this study,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    ) appears to be associated with a decrease in the likelihood of undergoing surgery for POP, according to a systematic review of randomized trials described above (see",
"    <a class=\"local\" href=\"#H8625211\">",
"     'Prevention'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/43\">",
"     43",
"    </a>",
"    ]. However, no data exist to support systemic or topical estrogen as a therapy for the treatment of POP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8624725\">",
"    <span class=\"h3\">",
"     Surgical treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical candidates include women with symptomatic prolapse who have failed or declined conservative management of their prolapse. There are numerous surgeries for prolapse including vaginal and abdominal approaches with and without graft materials.",
"   </p>",
"   <p>",
"    Surgical prognosis depends upon the severity of symptoms, extent of the prolapse, physician experience, and patient expectations. Surgery has traditionally been associated with a",
"    <span class=\"nowrap\">",
"     recurrence/reoperation",
"    </span>",
"    rate of up to 30 percent after the initial surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/18\">",
"     18",
"    </a>",
"    ], with some centers reporting reoperation in over 50 percent of patients who have undergone at least two prior surgical procedures for prolapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40473/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A detailed discussion of choosing a surgical therapy for prolapse can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9337?source=see_link\">",
"     \"Pelvic organ prolapse in women: Choosing a primary surgical procedure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     INFORMATION FOR PATIENTS",
"    </strong>",
"    &mdash; UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/60/11202?source=see_link\">",
"       \"Patient information: Pelvic muscle (Kegel) exercises (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/62/44001?source=see_link\">",
"       \"Patient information: Pelvic organ prolapse (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/0/19456?source=see_link\">",
"       \"Patient information: Pelvic floor muscle exercises (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pelvic organ prolapse (POP) is the herniation of the pelvic organs to or beyond the vaginal walls. (See",
"      <a class=\"local\" href=\"#H7156411\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Estimates of the prevalence of symptomatic POP range from 3 to 11 percent of women. (See",
"      <a class=\"local\" href=\"#H21524720\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for POP include: increasing parity, advancing age, obesity, and hysterectomy. Women with chronic constipation, those who have jobs that involve heavy lifting, and Latina and white women may also have an increased risk of POP. (See",
"      <a class=\"local\" href=\"#H21524727\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common symptom of prolapse is a",
"      <strong>",
"      </strong>",
"      sensation of pelvic",
"      <span class=\"nowrap\">",
"       pressure/heaviness",
"      </span>",
"      or protrusion of tissue from the vagina. Patients frequently describe this as &ldquo;feeling a bulge&rdquo; or like something is &ldquo;falling out of the vagina.&rdquo; Women with prolapse commonly have other pelvic floor disorders, including urinary, bowel and sexual complaints. (See",
"      <a class=\"local\" href=\"#H21524755\">",
"       'Clinical manifestations'",
"      </a>",
"      above.) Women with symptomatic prolapse can be managed expectantly, or treated with conservative or surgical therapy. Treatment is generally not indicated for women with asymptomatic prolapse. (See",
"      <a class=\"local\" href=\"#H7157266\">",
"       'Approach to management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conservative treatment options for women with POP include vaginal pessaries and pelvic floor muscle exercises. (See",
"      <a class=\"local\" href=\"#H8624710\">",
"       'Conservative management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical candidates include women with symptomatic prolapse, who have failed or declined conservative management of their prolapse. There are numerous surgeries for prolapse, including vaginal and abdominal approaches (open, laparoscopic, or robotic) and with and without graft materials. (See",
"      <a class=\"local\" href=\"#H8624725\">",
"       'Surgical treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/1\">",
"      Lowder JL, Ghetti C, Nikolajski C, et al. Body image perceptions in women with pelvic organ prolapse: a qualitative study. Am J Obstet Gynecol 2011; 204:441.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/2\">",
"      Sung VW, Washington B, Raker CA. Costs of ambulatory care related to female pelvic floor disorders in the United States. Am J Obstet Gynecol 2010; 202:483.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/3\">",
"      Oliphant SS, Jones KA, Wang L, et al. Trends over time with commonly performed obstetric and gynecologic inpatient procedures. Obstet Gynecol 2010; 116:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/4\">",
"      Wu JM, Hundley AF, Fulton RG, Myers ER. Forecasting the prevalence of pelvic floor disorders in U.S. Women: 2010 to 2050. Obstet Gynecol 2009; 114:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/5\">",
"      Bump RC, Mattiasson A, B&oslash; K, et al. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol 1996; 175:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/6\">",
"      Kenton K, Shott S, Brubaker L. Vaginal topography does not correlate well with visceral position in women with pelvic organ prolapse. Int Urogynecol J Pelvic Floor Dysfunct 1997; 8:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/7\">",
"      Summers A, Winkel LA, Hussain HK, DeLancey JO. The relationship between anterior and apical compartment support. Am J Obstet Gynecol 2006; 194:1438.",
"     </a>",
"    </li>",
"    <li>",
"     Stepp, KJ, Walters, MD. Anatomy of the lower urinary tract, rectum and pelvic floor. In: Urogynecology and Reconstructive Surgery, 3rd ed, Walters, M, Karram, M (Eds), Mosby, Philadelphia 2007. p. 24.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/9\">",
"      Barber MD. Contemporary views on female pelvic anatomy. Cleve Clin J Med 2005; 72 Suppl 4:S3.",
"     </a>",
"    </li>",
"    <li>",
"     Stepp, KJ, Walters, MD. Anatomy of the lower urinary tract, rectum, and pelvic floor. In: Urogynecology and Reconstructive Pelvic Surgery, 3rd ed., Walters, MD, Karram, MM (Eds), Mosby Elsevier, Philadelphia 2007. p.27.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/11\">",
"      Percy JP, Neill ME, Swash M, Parks AG. Electrophysiological study of motor nerve supply of pelvic floor. Lancet 1981; 1:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/12\">",
"      Nygaard I, Barber MD, Burgio KL, et al. Prevalence of symptomatic pelvic floor disorders in US women. JAMA 2008; 300:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/13\">",
"      Barber MD, Walters MD, Bump RC. Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFDI-20 and PFIQ-7). Am J Obstet Gynecol 2005; 193:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/14\">",
"      Tegerstedt G, Maehle-Schmidt M, Nyr&eacute;n O, Hammarstr&ouml;m M. Prevalence of symptomatic pelvic organ prolapse in a Swedish population. Int Urogynecol J Pelvic Floor Dysfunct 2005; 16:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/15\">",
"      Rortveit G, Brown JS, Thom DH, et al. Symptomatic pelvic organ prolapse: prevalence and risk factors in a population-based, racially diverse cohort. Obstet Gynecol 2007; 109:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/16\">",
"      Boyles SH, Weber AM, Meyn L. Procedures for pelvic organ prolapse in the United States, 1979-1997. Am J Obstet Gynecol 2003; 188:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/17\">",
"      Jones KA, Shepherd JP, Oliphant SS, et al. Trends in inpatient prolapse procedures in the United States, 1979-2006. Am J Obstet Gynecol 2010; 202:501.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/18\">",
"      Olsen AL, Smith VJ, Bergstrom JO, et al. Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstet Gynecol 1997; 89:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/19\">",
"      Smith FJ, Holman CD, Moorin RE, Tsokos N. Lifetime risk of undergoing surgery for pelvic organ prolapse. Obstet Gynecol 2010; 116:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/20\">",
"      Swift SE. The distribution of pelvic organ support in a population of female subjects seen for routine gynecologic health care. Am J Obstet Gynecol 2000; 183:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/21\">",
"      Hendrix SL, Clark A, Nygaard I, et al. Pelvic organ prolapse in the Women's Health Initiative: gravity and gravidity. Am J Obstet Gynecol 2002; 186:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/22\">",
"      Samuelsson EC, Victor FT, Tibblin G, Sv&auml;rdsudd KF. Signs of genital prolapse in a Swedish population of women 20 to 59 years of age and possible related factors. Am J Obstet Gynecol 1999; 180:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/23\">",
"      Jelovsek JE, Maher C, Barber MD. Pelvic organ prolapse. Lancet 2007; 369:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/24\">",
"      Sze EH, Sherard GB 3rd, Dolezal JM. Pregnancy, labor, delivery, and pelvic organ prolapse. Obstet Gynecol 2002; 100:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/25\">",
"      Mant J, Painter R, Vessey M. Epidemiology of genital prolapse: observations from the Oxford Family Planning Association Study. Br J Obstet Gynaecol 1997; 104:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/26\">",
"      Patel DA, Xu X, Thomason AD, et al. Childbirth and pelvic floor dysfunction: an epidemiologic approach to the assessment of prevention opportunities at delivery. Am J Obstet Gynecol 2006; 195:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/27\">",
"      Tinelli A, Malvasi A, Rahimi S, et al. Age-related pelvic floor modifications and prolapse risk factors in postmenopausal women. Menopause 2010; 17:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/28\">",
"      Swift S, Woodman P, O'Boyle A, et al. Pelvic Organ Support Study (POSST): the distribution, clinical definition, and epidemiologic condition of pelvic organ support defects. Am J Obstet Gynecol 2005; 192:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/29\">",
"      Kudish BI, Iglesia CB, Sokol RJ, et al. Effect of weight change on natural history of pelvic organ prolapse. Obstet Gynecol 2009; 113:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/30\">",
"      Daucher, JA, Ellison, RE, Lowder, JL. Pelvic support and urinary function improve in women after surgically induced weight reduction. Female Pelv Med &amp; Reconstr Surg 2010; 16:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/31\">",
"      Whitcomb EL, Rortveit G, Brown JS, et al. Racial differences in pelvic organ prolapse. Obstet Gynecol 2009; 114:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/32\">",
"      Sears CL, Wright J, O'Brien J, et al. The racial distribution of female pelvic floor disorders in an equal access health care system. J Urol 2009; 181:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/33\">",
"      Weber AM, Walters MD, Ballard LA, et al. Posterior vaginal prolapse and bowel function. Am J Obstet Gynecol 1998; 179:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/34\">",
"      Spence-Jones C, Kamm MA, Henry MM, Hudson CN. Bowel dysfunction: a pathogenic factor in uterovaginal prolapse and urinary stress incontinence. Br J Obstet Gynaecol 1994; 101:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/35\">",
"      J&oslash;rgensen S, Hein HO, Gyntelberg F. Heavy lifting at work and risk of genital prolapse and herniated lumbar disc in assistant nurses. Occup Med (Lond) 1994; 44:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/36\">",
"      Carley ME, Schaffer J. Urinary incontinence and pelvic organ prolapse in women with Marfan or Ehlers Danlos syndrome. Am J Obstet Gynecol 2000; 182:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/37\">",
"      Muir TW, Aspera AM, Rackley RR, Walters MD. Recurrent pelvic organ prolapse in a woman with bladder exstrophy: a case report of surgical management and review of the literature. Int Urogynecol J Pelvic Floor Dysfunct 2004; 15:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/38\">",
"      McIntosh LJ, Mallett VT, Frahm JD, et al. Gynecologic disorders in women with Ehlers-Danlos syndrome. J Soc Gynecol Investig 1995; 2:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/39\">",
"      Lince SL, van Kempen LC, Vierhout ME, Kluivers KB. A systematic review of clinical studies on hereditary factors in pelvic organ prolapse. Int Urogynecol J 2012; 23:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/40\">",
"      Hundley AF, Yuan L, Visco AG. Gene expression in the rectus abdominus muscle of patients with and without pelvic organ prolapse. Am J Obstet Gynecol 2008; 198:220.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/41\">",
"      Kluivers KB, Dijkstra JR, Hendriks JC, et al. COL3A1 2209G&gt;A is a predictor of pelvic organ prolapse. Int Urogynecol J Pelvic Floor Dysfunct 2009; 20:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/42\">",
"      Handa VL, Jones M. Do pessaries prevent the progression of pelvic organ prolapse? Int Urogynecol J Pelvic Floor Dysfunct 2002; 13:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/43\">",
"      Ismail SI, Bain C, Hagen S. Oestrogens for treatment or prevention of pelvic organ prolapse in postmenopausal women. Cochrane Database Syst Rev 2010; :CD007063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/44\">",
"      Swift SE, Tate SB, Nicholas J. Correlation of symptoms with degree of pelvic organ support in a general population of women: what is pelvic organ prolapse? Am J Obstet Gynecol 2003; 189:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/45\">",
"      Heit M, Rosenquist C, Culligan P, et al. Predicting treatment choice for patients with pelvic organ prolapse. Obstet Gynecol 2003; 101:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/46\">",
"      Ellerkmann RM, Cundiff GW, Melick CF, et al. Correlation of symptoms with location and severity of pelvic organ prolapse. Am J Obstet Gynecol 2001; 185:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/47\">",
"      Gutman RE, Ford DE, Quiroz LH, et al. Is there a pelvic organ prolapse threshold that predicts pelvic floor symptoms? Am J Obstet Gynecol 2008; 199:683.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/48\">",
"      Mouritsen L, Larsen JP. Symptoms, bother and POPQ in women referred with pelvic organ prolapse. Int Urogynecol J Pelvic Floor Dysfunct 2003; 14:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/49\">",
"      Kahn MA, Breitkopf CR, Valley MT, et al. Pelvic Organ Support Study (POSST) and bowel symptoms: straining at stool is associated with perineal and anterior vaginal descent in a general gynecologic population. Am J Obstet Gynecol 2005; 192:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/50\">",
"      Klingele CJ, Bharucha AE, Fletcher JG, et al. Pelvic organ prolapse in defecatory disorders. Obstet Gynecol 2005; 106:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/51\">",
"      Tan JS, Lukacz ES, Menefee SA, et al. Predictive value of prolapse symptoms: a large database study. Int Urogynecol J Pelvic Floor Dysfunct 2005; 16:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/52\">",
"      Bradley CS, Nygaard IE. Vaginal wall descensus and pelvic floor symptoms in older women. Obstet Gynecol 2005; 106:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/53\">",
"      Barber MD, Neubauer NL, Klein-Olarte V. Can we screen for pelvic organ prolapse without a physical examination in epidemiologic studies? Am J Obstet Gynecol 2006; 195:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/54\">",
"      Marinkovic SP, Stanton SL. Incontinence and voiding difficulties associated with prolapse. J Urol 2004; 171:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/55\">",
"      Patil A, Duckett JR. Effect of prolapse repair on voiding and bladder overactivity. Curr Opin Obstet Gynecol 2010; 22:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/56\">",
"      de Boer TA, Salvatore S, Cardozo L, et al. Pelvic organ prolapse and overactive bladder. Neurourol Urodyn 2010; 29:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/57\">",
"      Burrows LJ, Meyn LA, Walters MD, Weber AM. Pelvic symptoms in women with pelvic organ prolapse. Obstet Gynecol 2004; 104:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/58\">",
"      Tok EC, Yasa O, Ertunc D, et al. The effect of pelvic organ prolapse on sexual function in a general cohort of women. J Sex Med 2010; 7:3957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/59\">",
"      Weber AM, Walters MD, Piedmonte MR. Sexual function and vaginal anatomy in women before and after surgery for pelvic organ prolapse and urinary incontinence. Am J Obstet Gynecol 2000; 182:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/60\">",
"      Weber AM, Walters MD, Schover LR, Mitchinson A. Sexual function in women with uterovaginal prolapse and urinary incontinence. Obstet Gynecol 1995; 85:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/61\">",
"      Barber MD, Visco AG, Wyman JF, et al. Sexual function in women with urinary incontinence and pelvic organ prolapse. Obstet Gynecol 2002; 99:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/62\">",
"      Novi JM, Jeronis S, Morgan MA, Arya LA. Sexual function in women with pelvic organ prolapse compared to women without pelvic organ prolapse. J Urol 2005; 173:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/63\">",
"      Bradley CS, Zimmerman MB, Qi Y, Nygaard IE. Natural history of pelvic organ prolapse in postmenopausal women. Obstet Gynecol 2007; 109:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/64\">",
"      Handa VL, Garrett E, Hendrix S, et al. Progression and remission of pelvic organ prolapse: a longitudinal study of menopausal women. Am J Obstet Gynecol 2004; 190:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/65\">",
"      Dietz HP. Prolapse worsens with age, doesn't it? Aust N Z J Obstet Gynaecol 2008; 48:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/66\">",
"      Elkadry EA, Kenton KS, FitzGerald MP, et al. Patient-selected goals: a new perspective on surgical outcome. Am J Obstet Gynecol 2003; 189:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/67\">",
"      Hullfish KL, Bovbjerg VE, Steers WD. Patient-centered goals for pelvic floor dysfunction surgery: long-term follow-up. Am J Obstet Gynecol 2004; 191:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/68\">",
"      Mahajan ST, Elkadry EA, Kenton KS, et al. Patient-centered surgical outcomes: the impact of goal achievement and urge incontinence on patient satisfaction one year after surgery. Am J Obstet Gynecol 2006; 194:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/69\">",
"      Culligan PJ. Nonsurgical management of pelvic organ prolapse. Obstet Gynecol 2012; 119:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/70\">",
"      Hagen S, Stark D. Conservative prevention and management of pelvic organ prolapse in women. Cochrane Database Syst Rev 2011; :CD003882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/71\">",
"      Braekken IH, Majida M, Engh ME, B&oslash; K. Can pelvic floor muscle training reverse pelvic organ prolapse and reduce prolapse symptoms? An assessor-blinded, randomized, controlled trial. Am J Obstet Gynecol 2010; 203:170.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40473/abstract/72\">",
"      Whiteside JL, Weber AM, Meyn LA, Walters MD. Risk factors for prolapse recurrence after vaginal repair. Am J Obstet Gynecol 2004; 191:1533.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8072 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D4C8FA2A70-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_33_40473=[""].join("\n");
var outline_f39_33_40473=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21524713\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7156411\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H690213\">",
"      ANATOMY OF PELVIC SUPPORT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H690220\">",
"      Levels of pelvic organ support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H691664\">",
"      Nerve supply",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21524720\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21524727\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H691443\">",
"      Parity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H691457\">",
"      Advancing age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H691464\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H691472\">",
"      Hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7156775\">",
"      Race and ethnicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1841428\">",
"      Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8625211\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21524755\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1842335\">",
"      Bulge or pressure symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24639614\">",
"      Urinary symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21524762\">",
"      Defecatory symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24639741\">",
"      Effects on sexual function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7156639\">",
"      DIAGNOSIS AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8625139\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7157266\">",
"      APPROACH TO MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13817287\">",
"      Indications for treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7157274\">",
"      Establishing patient goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13817294\">",
"      Management options",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7157464\">",
"      - Expectant management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8624710\">",
"      - Conservative management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8624733\">",
"      Vaginal pessary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8624747\">",
"      Pelvic floor muscle exercises",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6514468\">",
"      Estrogen therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8624725\">",
"      - Surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/8072\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/8072|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/63/15349\" title=\"figure 1\">",
"      Pelvic organ prolapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/45/34513\" title=\"figure 2\">",
"      Female pelvic bones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/8/25736\" title=\"figure 3\">",
"      Pelvic floor muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/27/6586\" title=\"figure 4\">",
"      Pelvic floor muscles 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/56/6026\" title=\"figure 5\">",
"      Bones and ligaments of the pelvis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/4/26693\" title=\"figure 6\">",
"      Delancey levels pelvic support 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/8072|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/19/39218\" title=\"picture 1\">",
"      Posterior vaginal prolapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/39/30322\" title=\"picture 2\">",
"      Complete uterine prolapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/54/20320\" title=\"picture 3\">",
"      Complete vaginal vault prolapse",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/19/12602?source=related_link\">",
"      Overview of hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/0/19456?source=related_link\">",
"      Patient information: Pelvic floor muscle exercises (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/60/11202?source=related_link\">",
"      Patient information: Pelvic muscle (Kegel) exercises (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/62/44001?source=related_link\">",
"      Patient information: Pelvic organ prolapse (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/18/19753?source=related_link\">",
"      Pelvic floor disorders associated with pregnancy and childbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/32/1546?source=related_link\">",
"      Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9337?source=related_link\">",
"      Pelvic organ prolapse in women: Choosing a primary surgical procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/46/8937?source=related_link\">",
"      Pelvic organ prolapse in women: Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/7/17530?source=related_link\">",
"      Vaginal pessary treatment of prolapse and incontinence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_33_40474="Cellular and molecular biology of chronic myeloid leukemia";
var content_f39_33_40474=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cellular and molecular biology of chronic myeloid leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/33/40474/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/33/40474/contributors\">",
"     Richard A Van Etten, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/33/40474/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/33/40474/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/33/40474/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/33/40474/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/33/40474/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic myeloid leukemia (CML, also known as chronic myelocytic or chronic myelogenous leukemia) is classified as one of the myeloproliferative neoplasms, along with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/52/21322?source=see_link\">",
"     \"Overview of the myeloproliferative neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This group of diseases shares several distinct features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They are clonal disorders of hematopoiesis that arise in a hematopoietic stem or early progenitor cell.",
"     </li>",
"     <li>",
"      They are characterized by the dysregulated production of a particular lineage of mature myeloid cells with fairly normal differentiation.",
"     </li>",
"     <li>",
"      They exhibit a variable tendency to progress to acute leukemia.",
"     </li>",
"     <li>",
"      They share abnormalities of hemostasis and thrombosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The individual myeloproliferative neoplasms predominantly affect a single myeloid cell type, resulting in an excess of neutrophils in CML, erythrocytes in PV, and platelets in ET. However, there is considerable overlap between the clinical features as patients with CML, for example, often have thrombocytosis.",
"   </p>",
"   <p>",
"    CML is almost invariably associated an abnormal chromosome 22 known as the Philadelphia chromosome, often abbreviated as Ph, Ph(1), or Ph",
"    <sup>",
"     1",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The Philadelphia chromosome t(9;22)(q34;q11) results in the formation of a unique gene product (BCR-ABL1), which is a constitutively active tyrosine kinase. This deregulated tyrosine kinase is implicated in the development of CML and has become a primary target for the treatment of this disorder.",
"   </p>",
"   <p>",
"    The cellular and molecular biology of CML will be reviewed here. The molecular genetics of this disorder, including the Philadelphia chromosome and its protein product, are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31512?source=see_link\">",
"     \"Molecular genetics of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6496975\">",
"    <span class=\"h1\">",
"     CELL OF ORIGIN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2792128\">",
"    <span class=\"h2\">",
"     Normal counterpart",
"    </span>",
"    &nbsp;&mdash;&nbsp;CML is a clonal myeloproliferative neoplasm derived from an abnormal pluripotent hematopoietic stem cell that has acquired the BCR-ABL1 fusion gene, usually through t(9;22)(q34;q11), also known as the Philadelphia chromosome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clonal nature of CML and other myeloproliferative neoplasms was confirmed in complementary clonality studies in women with CML utilizing isozymes of the X-chromosome linked enzyme glucose 6-phosphate dehydrogenase (G6PD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/4\">",
"     4",
"    </a>",
"    ] or methylation-sensitive restriction fragment length polymorphisms in X-linked genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/5\">",
"     5",
"    </a>",
"    ]. The derivation of this clonal population from a pluripotent hematopoietic stem cell was first supported by cytogenetic studies that demonstrated the Ph chromosome in granulocyte, monocyte, and erythroid precursors, megakaryocytes, and most B-lymphocytes from patients with CML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequent findings supported the role of a pluripotent hematopoietic stem cell progenitor as the cell of origin:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BCR-ABL1 mRNA can be found in CD34+ (progenitor) subpopulations from patients with CML [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Leukemia stem cells in mice are Lin-c-Kit+Sca-1+, a known phenotype of hematopoietic stem cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Approximately one-third of CD3+ T lymphocytes are Ph-positive in chronic phase CML [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When CML progresses to acute phase, the blast cells may be of myeloid or lymphoid phenotype and are invariably found to carry the Ph chromosome, suggesting that they arise from the same leukemic clone as the chronic phase cells. Interestingly, peripheral blood T lymphocytes from patients with CML are often Ph-negative [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/10\">",
"       10",
"      </a>",
"      ], perhaps because normal T cells are long-lived and preferentially responsive to the mitogen stimulation necessary for metaphase analysis.",
"     </li>",
"     <li>",
"      Although rare, several cases of Ph-positive T-lymphoid blast crisis have been reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/11\">",
"       11",
"      </a>",
"      ], suggesting that the disease involves a pluripotent cell capable of differentiating to T-lymphoid cells as well as myeloid and B-lymphoid cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the aggregate, these studies strongly support the hypothesis that CML is a clonal malignancy involving the pluripotent hematopoietic stem cell. By contrast, CML in blast crisis appears to be derived from a BCR-ABL1 transformed granulocyte macrophage progenitor rather than a more primitive hematopoietic stem cell [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7228199\">",
"     'Progression to acute phase CML'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2791988\">",
"    <span class=\"h2\">",
"     The leukemia stem cell",
"    </span>",
"    &nbsp;&mdash;&nbsp;All leukemias, including CML, appear to be maintained by a pool of self-renewing malignant cells, as assessed by their ability to transfer the disease upon xenotransplantation into immunodeficient mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/14\">",
"     14",
"    </a>",
"    ]. These leukemic stem cells (LSC, also leukemia-initiating cells) may be more immature than the majority of circulating leukemic cells, and are thought to have originated from cells with existing self-renewal capacity or from progenitors that have re-acquired this stem cell-like property [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/33/35354?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis of acute myeloid leukemia\", section on 'Cell of origin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    LSCs may be identified in the laboratory by the following features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      LSCs engraft after transplantation and can be transplanted serially.",
"     </li>",
"     <li>",
"      Transplantation of LSCs in xenografts results in morphologic and immunophenotypic recapitulation of the CML tumor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In chronic phase CML, the Ph chromosome translocation occurs in a hematopoietic stem cell (HSC) with the capacity for multilineage differentiation and self-renewal. The size of this HSC compartment, as defined by cell surface antigen expression, is normal, while committed myeloid progenitors and granulocyte-macrophage progenitors (CFU-GM) are significantly increased in number [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/17\">",
"     17",
"    </a>",
"    ]. Studies in mouse model systems demonstrate that BCR-ABL1 does not confer self-renewal capacity to committed myeloid progenitors, and sustained CML-like leukemia cannot be produced by transplantation of BCR-ABL1-expressing committed progenitors into recipient mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/18\">",
"     18",
"    </a>",
"    ]. This helps to explain why the Ph chromosome translocation is present in a pluripotent hematopoietic stem cell even though CML predominantly affects the neutrophil lineage: stem cell origin is required for maintenance of the disease in the bone marrow.",
"   </p>",
"   <p>",
"    Interestingly, even though the BCR-ABL1 kinase is active in CML LSCs, CML LSCs exposed to tyrosine kinase inhibitors are not dependent upon BCR-ABL1 kinase activity for survival, but instead revert to dependence on cytokines that normally mediate survival and proliferation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/19-23\">",
"     19-23",
"    </a>",
"    ]. As such, efforts are ongoing to identify survival pathways in LSCs that may be targeted. As an example, initial studies in mice suggest that the B-lymphoid kinase (Blk) gene acts as a tumor suppressor in CML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/24\">",
"     24",
"    </a>",
"    ]. In these models, BCR-ABL1 acts through the transcriptional regulator c-Myc to downregulate the Blk gene in LSCs. The restoration of Blk expression or the expression of other genes in the Blk pathway suppresses LSCs without impairing normal hematopoietic stem cells or hematopoiesis.",
"   </p>",
"   <p>",
"    Several research groups have used mathematical modeling in an attempt to predict disease progression and control. As yet, the clinical utility of these measures is unknown. Studies of BCR-ABL1 transcript dynamics in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    have revealed an initial rapid decline in the majority of patients, followed by a slower rate of decrease. Mathematical models suggest that the first phase represents elimination of mature cells and committed progenitors, while the slower decline may reflect a gradual decrease in the LSC population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Although patients who experience a more rapid decrease in the putative LSC population have superior overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/25\">",
"     25",
"    </a>",
"    ], further prospective studies are necessary to determine if this parameter can be used to identify patients who might safely discontinue TKI therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     THE BCR-ABL1 FUSION PROTEIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The protein product of the Philadelphia chromosome, the BCR-ABL1 fusion protein, is unique to the leukemic cells and is the fundamental cause of all the abnormalities observed in the Ph-positive leukemias. Understanding the functions of this protein and those encoded by the normal cellular genes involved in the Ph translocation, c-ABL1 and BCR, is essential to elucidate the molecular pathophysiology of these leukemias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31512?source=see_link\">",
"     \"Molecular genetics of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While much is known regarding the structure of the BCR and c-ABL1 genes that come together to form the BCR-ABL1 fusion gene, there is limited information on their normal function. The protein products of these genes have no intrinsic oncogenic properties. However, together they produce the BCR-ABL1 fusion protein which is essential for the development of CML.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     BCR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The product of the BCR (breakpoint cluster region) gene is a ubiquitously expressed 1271 amino acid cytoplasmic phosphoprotein of 160 kDa molecular mass that has several known functional domains (",
"    <a class=\"graphic graphic_figure graphicRef66610 \" href=\"mobipreview.htm?9/41/9886\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first exon-encoded sequences (amino acids 1-427), BCR contains a coiled-coil domain that mediates homo-oligomerization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/32\">",
"       32",
"      </a>",
"      ] and a novel serine kinase activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The middle of the protein (amino acids 490 to 690; encoded by exons 3 to 10) contains a region of homology to the Dbl oncoprotein (with an associated pleckstrin homology domain) that functions as a guanine nucleotide exchange factor for Rho proteins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The C-terminus of BCR contains a domain with GTPase activating protein (GAP) homology and GAP activity toward the Rac and Cdc42 proteins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/35\">",
"       35",
"      </a>",
"      ]. The BCR gene has been inactivated in mice by homologous recombination; mice lacking BCR show an increased respiratory burst in their neutrophils as a result of loss of downregulation of p21Rac-mediated activation of neutrophil NADPH oxidase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The normal function of the BCR gene product is not known and it has no intrinsic oncogenic properties.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     c-ABL1",
"    </span>",
"    &nbsp;&mdash;&nbsp;The c-ABL1 gene contains 11 exons with two alternative 5' exons, and produces two proteins (types Ia and Ib ABL1, also called types I and IV c-Abl in mice) of 1122 and 1142 amino acids, respectively, that differ in sequence only at their N-termini (",
"    <a class=\"graphic graphic_figure graphicRef66610 \" href=\"mobipreview.htm?9/41/9886\">",
"     figure 1",
"    </a>",
"    ). Type Ib c-ABL1 is covalently modified by myristoyl fatty acid at an N-terminal glycine residue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The c-ABL1 proteins are similar to the Src family of non-receptor protein-tyrosine kinases, and can phosphorylate cellular proteins on tyrosine residues. However, c-ABL1 has a large C-terminal domain of about 80 kDa that is not found in the Src proteins, which ends just after the catalytic domain. Thus, the c-ABL1 gene and a related gene (called ABL-related gene or",
"    <span class=\"nowrap\">",
"     ARG/ABL2)",
"    </span>",
"    comprise a unique family, with recognizable orthologues in the genomes of C. elegans and Drosophila.",
"   </p>",
"   <p>",
"    The normal function of the ABL1 proteins is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/38\">",
"     38",
"    </a>",
"    ]. c-ABL1 is localized to the cell nucleus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/39\">",
"     39",
"    </a>",
"    ] and the F-actin cytoskeleton [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/40\">",
"     40",
"    </a>",
"    ], and may be involved in the cell response to genotoxic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/41\">",
"     41",
"    </a>",
"    ] and oxidative stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/42\">",
"     42",
"    </a>",
"    ], and in integrin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/43\">",
"     43",
"    </a>",
"    ] and platelet-derived growth factor (PDGF) signaling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/44\">",
"     44",
"    </a>",
"    ]. c-ABL1 tyrosine kinase activity is tightly controlled in the cell, and appears to be regulated at multiple levels by serine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/45\">",
"     45",
"    </a>",
"    ] and tyrosine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/44,46\">",
"     44,46",
"    </a>",
"    ] phosphorylation, by NH2-terminal sequences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/47\">",
"     47",
"    </a>",
"    ], and by a cellular inhibitor that binds to the Src homology 3 (SH3) domain on c-ABL1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/42,48\">",
"     42,48",
"    </a>",
"    ]. Mice lacking c-ABL1 exhibit poor postnatal viability from an unknown cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/49,50\">",
"     49,50",
"    </a>",
"    ], and have defects in lymphoid development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/51\">",
"     51",
"    </a>",
"    ] and spermatogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     BCR-ABL1",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several distinct BCR-ABL1 fusion proteins generated from the Ph chromosome translocation, depending upon the site of the breakpoint on chromosome 22 (",
"    <a class=\"graphic graphic_figure graphicRef66610 \" href=\"mobipreview.htm?9/41/9886\">",
"     figure 1",
"    </a>",
"    ). Most patients with CML and one-third of those with Ph-positive B cell acute lymphoblastic leukemia (Ph+ B-cell ALL) are characterized by p210",
"    <sup>",
"     BCR-ABL1",
"    </sup>",
"    . Two-thirds of patients with Ph+ B-cell ALL and a minority of patients with CML demonstrate p190",
"    <sup>",
"     BCR-ABL1",
"    </sup>",
"    . The p230",
"    <sup>",
"     BCR-ABL1",
"    </sup>",
"    is seen in chronic neutrophilic leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31512?source=see_link&amp;anchor=H4596194#H4596194\">",
"     \"Molecular genetics of chronic myeloid leukemia\", section on 'Distinct forms of BCR-ABL1 from alternative chromosome 22 breakpoints'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The three principal forms of BCR-ABL1 (p190, p210, and p230 BCR-ABL1) contain all of c-ABL1 except the first exon-encoded sequence, including the entire ABL tyrosine kinase catalytic domain, but have different amounts of BCR sequence at the N-terminus (",
"      <a class=\"graphic graphic_figure graphicRef66610 \" href=\"mobipreview.htm?9/41/9886\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      All three forms of BCR-ABL1 contain the Bcr exon coiled-coil domain, but only p210 and p230 include the",
"      <span class=\"nowrap\">",
"       Dbl/pleckstrin",
"      </span>",
"      homology domain from the central portion of BCR. The C-terminal GAP domain of BCR is not included in p190 and p210, but a portion is retained in the longer p230 fusion protein.",
"     </li>",
"     <li>",
"      All three forms of BCR-ABL1 have increased tyrosine kinase activity in vivo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/54\">",
"       54",
"      </a>",
"      ] and in vitro [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/55,56\">",
"       55,56",
"      </a>",
"      ] relative to c-ABL1, due to the addition of BCR exon 1 sequences to Abl. When quantitated in an immune complex kinase assay, p190 has the highest intrinsic kinase activity, followed by p210 and p230 (about 10-, 6-, and 3-fold increased over that of c-ABL1, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/55,56\">",
"       55,56",
"      </a>",
"      ]. The different kinase activity of the BCR-ABL1 isoforms may in part account for the distinct leukemias associated with the different fusions, and may predict responsiveness to therapy with tyrosine kinase inhibitors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The precise mode of activation of ABL1 kinase activity by BCR is unknown, but may involve several distinct mechanisms including oligomerization of BCR-ABL1 via the coiled-coil domain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/32\">",
"     32",
"    </a>",
"    ], and interaction of BCR with the ABL1 Src homology 2 (SH2) domain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/57\">",
"     57",
"    </a>",
"    ], blocking the binding of an Abl inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/42\">",
"     42",
"    </a>",
"    ]. Unlike c-ABL1, BCR-ABL1 is localized exclusively in the cytoplasm of hematopoietic cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/58\">",
"     58",
"    </a>",
"    ] in association with subcortical F-actin-rich structures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/59\">",
"     59",
"    </a>",
"    ]. BCR-ABL1 can be trapped in the nucleus by treatment of cells with a combination of an ABL1 kinase inhibitor and leptomycin-B, an inhibitor of nuclear export [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/60\">",
"     60",
"    </a>",
"    ]. Removal of the ABL1 kinase inhibitor then induces apoptosis through activation of BCR-ABL1 kinase activity in the nucleus, which may have applications for in vitro purging of CML cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2788069\">",
"    <span class=\"h1\">",
"     ESTABLISHMENT OF CHRONIC PHASE CML",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with CML present with relatively indolent disease (termed chronic phase) characterized by splenomegaly and leukocytosis with a white blood cell differential showing virtually all cells of the neutrophilic series, from myeloblasts to mature neutrophils with peaks in the percent myelocytes and segmented neutrophils [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/3\">",
"     3",
"    </a>",
"    ]. The granulocytes of chronic phase are morphologically normal, but cytochemically abnormal. This unusual phenotype is due to distinct abnormalities in hematopoiesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/28,61\">",
"     28,61",
"    </a>",
"    ]. The CML progenitors appear to have an alteration in the balance between self-renewal and differentiation that favors differentiation, an abnormality termed discordant maturation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19609?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations and diagnosis of chronic myeloid leukemia\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While initial studies suggested that clonality in CML may occur before the acquisition of Philadelphia chromosome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/63\">",
"     63",
"    </a>",
"    ], separate clonality studies demonstrated that Ph-negative CD34+ progenitors from patients with early chronic phase CML were polyclonal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/64\">",
"     64",
"    </a>",
"    ]. These results indicate that clonal hematopoiesis does not typically precede the acquisition of the Ph chromosome in the pathogenesis of CML and supports the leading hypothesis that the Philadelphia chromosome is the inciting event in CML.",
"   </p>",
"   <p>",
"    The development of chronic phase CML appears to be a direct result of BCR-ABL1 activity, which promotes its development by allowing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Uncontrolled proliferation of transformed cells (see",
"      <a class=\"local\" href=\"#H2788925\">",
"       'Uncontrolled proliferation'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Discordant maturation (see",
"      <a class=\"local\" href=\"#H2793233\">",
"       'Discordant maturation'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Escape from apoptosis (see",
"      <a class=\"local\" href=\"#H2788932\">",
"       'Escape from apoptosis'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Altered interaction with the cellular matrix (see",
"      <a class=\"local\" href=\"#H2788939\">",
"       'Altered interaction with the cellular matrix'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The BCR and c-ABL1 proteins have no intrinsic oncogenic properties and cannot transform cells, even if overexpressed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/37\">",
"     37",
"    </a>",
"    ]. By contrast, the BCR-ABL1 protein has gained the ability to transform cell lines and primary cells in vitro, demonstrating that it is a classical oncogene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/65\">",
"     65",
"    </a>",
"    ]. The primary action of BCR-ABL1 in B-lymphoid progenitors appears to be stimulation of proliferation rather than oncogenic transformation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/66\">",
"     66",
"    </a>",
"    ], suggesting that multiple steps may be required for B-lymphoid transformation by BCR-ABL1. A multiple step model is also supported by studies in patients with known exposure to ionizing radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/67,68\">",
"     67,68",
"    </a>",
"    ] that have demonstrated a delay of several years between the initial mutational event (presumably, the acquisition of the Ph chromosome translocation in a stem cell) and the development of clinical symptoms that lead to the diagnosis of CML.",
"   </p>",
"   <p>",
"    All forms of BCR-ABL1 can transform cytokine-dependent lymphoid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/56,69\">",
"     56,69",
"    </a>",
"    ] and myeloid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/56,70\">",
"     56,70",
"    </a>",
"    ] hematopoietic cell lines to become independent of cytokine for survival and proliferation. Although BCR-ABL1 can induce secretion of cytokines (including IL-3) in some cytokine-dependent hematopoietic cell lines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/70,71\">",
"     70,71",
"    </a>",
"    ], transformation of these cells by BCR-ABL1 does not require autocrine production of cytokine. BCR-ABL1 can also stimulate the growth of primary murine bone marrow-derived B-lymphoid progenitors in vitro, leading to the outgrowth of transformed pre-B cells that are independent of growth factors and stroma, and are leukemogenic upon transfer to syngeneic or immunodeficient recipient mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/72\">",
"     72",
"    </a>",
"    ]. The p190 form of BCR-ABL1 is more potent than p210 in this growth stimulatory assay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2791725\">",
"    <span class=\"h2\">",
"     BCR-ABL1 signaling",
"    </span>",
"    &nbsp;&mdash;&nbsp;BCR-ABL1 induces leukemogenesis through kinase dependent and kinase independent signalling pathways. Presumably, the specific cellular abnormalities observed in CML are the consequence of aberrant intracellular signaling. If this is correct, then an attempt can be made to correlate particular signaling pathways with specific cellular responses. Through the use of chemical inhibitors, dominant-negative mutants, and genetically deficient cells and mice, it has been possible to demonstrate that some of the signaling pathways are required for transformation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    leukemogenesis by BCR-ABL1, validating these downstream pathways as targets for rational therapy of Ph-positive leukemia. However, there is considerable overlap and redundancy between the different pathways, and activation of multiple pathways is probably required for the complete leukemic phenotype in vivo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2793041\">",
"    <span class=\"h3\">",
"     Tyrosine kinase activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;BCR-ABL1 is a constitutively active tyrosine kinase. The tyrosine kinase activity of ABL1 is absolutely required for transformation by BCR-ABL1, as evidenced by the observation that mutations in the catalytic domain that inactivate kinase activity also abolish transformation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/75\">",
"     75",
"    </a>",
"    ]. Similarly, mutations in ABL1 that render the catalytic activity sensitive to temperature, inactivate transformation at the non-permissive temperature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BCR-ABL1 induces tyrosine phosphorylation of a large number of cellular proteins in hematopoietic cells. As a result, a diverse group of intracellular signaling pathways is activated by BCR-ABL1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/78\">",
"     78",
"    </a>",
"    ], in part through induction of protein complexes between tyrosine-phosphorylated proteins and SH2-containing proteins. Some of these pathways overlap with signaling induced by hematopoietic cytokines such as IL-3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A central role for the BCR-ABL1 tyrosine kinase in the pathogenesis of CML has been established by the therapeutic efficacy of small molecule inhibitors of the ABL1 tyrosine kinase. Specific BCR-ABL1 tyrosine kinase inhibitors decrease cellular proliferation of BCR-ABL1-expressing cells in vitro by more than 90 percent but have minimal effects on normal cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. The applicability of these findings to humans was initially illustrated in a clinical trial in which 31 of 31 patients with CML in chronic phase achieved clinical complete remission after receiving an orally active, specific inhibitor of the ABL1 protein tyrosine kinase.",
"   </p>",
"   <p>",
"    Tyrosine kinase inhibitors have become the standard therapy for most patients with CML. While these agents have a high rate of long-term disease control, they are not able to cure CML. The inability of tyrosine kinase inhibitors to cure CML is thought to reflect a natural resistance of at least a population of leukemia stem cells to these agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/16/41225?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of the treatment of chronic myeloid leukemia\", section on 'Tyrosine kinase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2793048\">",
"    <span class=\"h3\">",
"     Kinase independent pathways",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, signalling by BCR-ABL1 is thought to manifest through both kinase dependent and kinase independent pathways. Support for this comes from studies that have shown leukemia stem cells to be inherently resistant to tyrosine kinase inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/20,82,83\">",
"     20,82,83",
"    </a>",
"    ]. In addition, mutations of BCR-ABL1 have been identified that impair leukemogenesis despite preserving tyrosine kinase activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/84\">",
"     84",
"    </a>",
"    ]. DNA microarray analyses of CML cells and other studies have implicated many kinase independent pathways in the pathogenesis of CML including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/85-91\">",
"     85-91",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Wnt/Beta-catenin",
"      </span>",
"      pathway &ndash; Involved in the development of hematopoietic stem cells",
"     </li>",
"     <li>",
"      Hedgehog pathway &ndash; Critical for primitive hematopoiesis",
"     </li>",
"     <li>",
"      Alox5 pathway &ndash; Part of the oxidative stress response, inflammation, and other types of cancer development",
"     </li>",
"     <li>",
"      PTEN pathway &ndash; Regulates cell survival and growth",
"     </li>",
"     <li>",
"      FoxO pathway &ndash; Mediates cell-cycle arrest, stress resistance and apoptosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The magnitude of effect of these kinase independent pathways is not well understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2788925\">",
"    <span class=\"h2\">",
"     Uncontrolled proliferation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In established CML, the pool of Ph-positive committed myeloid progenitors in marrow and blood is greatly expanded due at least in part to increased proliferation. This was initially suggested by the predominance of Ph-positive bone marrow metaphases (90 to 100 percent) at diagnosis in most patients and later confirmed by in vivo labeling studies with tritiated thymidine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/92\">",
"     92",
"    </a>",
"    ]. However, the several year latency period in CML from mutation to disease development suggests that the relative magnitude of this advantage is quite small, as also evidenced by the following observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal stem cells persist in the bone marrow of patients with CML [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/93,94\">",
"       93,94",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients diagnosed early in the disease course exhibit significant residual Ph-negative hematopoiesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/95\">",
"       95",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    BCR-ABL1 has primary mitogenic activity and can stimulate cell cycle entry of hematopoietic cell lines and primary cells in the absence of growth factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. While many signalling pathways participate, activation of the MAP kinase (MAPK) pathway appears to play a central role in the promotion of uncontrolled proliferation. BCR-ABL1 activates p21 Ras and the downstream",
"    <span class=\"nowrap\">",
"     Raf/MEK/MAPK",
"    </span>",
"    pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/96,98\">",
"     96,98",
"    </a>",
"    ] that probably plays a role in mitogenesis, as evidenced by the observation that Ras is required for fibroblast and B-lymphoid transformation by BCR-ABL1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/99\">",
"     99",
"    </a>",
"    ]. There are at least two independent mechanisms of Ras activation by BCR-ABL1: direct binding of the Grb2 adapter protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/84,100\">",
"     84,100",
"    </a>",
"    ]; and activation of the Shc adapter protein by tyrosine phosphorylation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The signaling activity of some Ras proteins requires association of the proteins with the plasma membrane. This in turn requires attachment of a farnesyl group (15-carbon lipid tail) to the protein, a reaction catalyzed by the enzyme, farnesyl transferase. Inhibition of this step by a farnesyl transferase inhibitor (FTI) is a potentially useful antineoplastic strategy in CML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19674?source=see_link\">",
"     \"Experimental treatment approaches for malignant gliomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39114?source=see_link\">",
"     \"Chemotherapy for advanced exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    BCR-ABL1 also has other important effects on pathways associated with uncontrolled proliferation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It activates the stress-activated protein",
"      <span class=\"nowrap\">",
"       kinase/Jun",
"      </span>",
"      N-terminal kinase",
"      <span class=\"nowrap\">",
"       (SAPK/JNK)",
"      </span>",
"      pathway [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/104\">",
"       104",
"      </a>",
"      ], which contributes to fibroblast and B-lymphoid transformation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/105\">",
"       105",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It is a potent activator of the",
"      <span class=\"nowrap\">",
"       JAK/STAT",
"      </span>",
"      pathway [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/106-109\">",
"       106-109",
"      </a>",
"      ]. Activation of STAT5 contributes to transformation by BCR-ABL1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/110,111\">",
"       110,111",
"      </a>",
"      ], at least in part through stimulation of proliferation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/112,113\">",
"       112,113",
"      </a>",
"      ]. The p190 form of BCR-ABL1 preferentially activates STAT6, which may contribute to the increased efficiency of B-lymphoid transformation by this isoform [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/108\">",
"       108",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Retroviral transduction'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Both c-MYC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/114\">",
"       114",
"      </a>",
"      ] and cyclin D1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/115\">",
"       115",
"      </a>",
"      ] are required for BCR-ABL1-induced mitogenesis and encourage cell cycle progression. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44054?source=see_link&amp;anchor=H6#H6\">",
"       \"Pathobiology of mantle cell lymphoma\", section on 'Cyclin D1 expression'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ph+ myeloid progenitors (CFU-C) have the same requirement for and sensitivity to hematopoietic cytokines as normal CFU-C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/116\">",
"     116",
"    </a>",
"    ], and patients with CML do not typically have increased plasma levels of cytokines. Aberrant mRNA transcripts for interleukin (IL)-3 and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) have been detected in the most primitive Ph+",
"    <span class=\"nowrap\">",
"     progenitor/stem",
"    </span>",
"    cells; neutralizing antibody experiments suggest that these cytokines contribute to autonomous growth and differentiation of these cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/117\">",
"     117",
"    </a>",
"    ]. However, the IL-3 gene is not required for induction of CML-like myeloproliferative disease by BCR-ABL1 in a mouse model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/118\">",
"     118",
"    </a>",
"    ]. In comparison, primitive Ph+ progenitors appear to be insensitive to chemokines produced by marrow stroma, such as monocyte chemoattractant protein-1 (MCP-1), which inhibit the growth of normal progenitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/119\">",
"     119",
"    </a>",
"    ]. However, the precise role of cytokines in the pathogenesis of CML requires further study. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Mouse models of CML'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2793233\">",
"    <span class=\"h2\">",
"     Discordant maturation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CML progenitors appear to have an alteration in the balance between self-renewal and differentiation that favors differentiation, an abnormality termed discordant maturation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/62\">",
"     62",
"    </a>",
"    ]. This observation is consistent with the finding that, in the chronic phase of CML, the size of the BCR-ABL1-containing, self-renewing, beta-catenin positive stem cells is normal, while that of the BCR-ABL1-containing, beta-catenin negative differentiating progenitor cells is expanded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/12\">",
"     12",
"    </a>",
"    ]. This suggests that, in the chronic phase, the mutant BCR-ABL1 protein affects a more critical function in progenitor cells than it does in the stem cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/120\">",
"     120",
"    </a>",
"    ]. However, in the blast crisis of CML, the granulocyte-macrophage progenitors unexpectedly accumulate beta-catenin, normally found only in stem cells, and have appear to have self-renewing properties (see",
"    <a class=\"local\" href=\"#H2791988\">",
"     'The leukemia stem cell'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H7228199\">",
"     'Progression to acute phase CML'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2788932\">",
"    <span class=\"h2\">",
"     Escape from apoptosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The survival of mature Ph+ neutrophils in patients with CML is only modestly prolonged and cannot account for the dramatic increase in granulocytes characteristic of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vitro, cytokine-dependent hematopoietic cell lines expressing BCR-ABL1 are protected from apoptosis (the process of programmed cell death) upon cytokine withdrawal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Philadelphia positive (Ph+) cell lines are also resistant to apoptosis induced by radiation and cytotoxic chemotherapeutic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/122\">",
"     122",
"    </a>",
"    ]. In contrast to these findings in cell lines, conflicting results have been obtained in primary CD34+ CML cells. While one group found that CD34+ cells from patients with CML were resistant to apoptosis induced by serum withdrawal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/123\">",
"     123",
"    </a>",
"    ] or ionizing radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/124\">",
"     124",
"    </a>",
"    ], others have not observed prolonged survival of primary Ph+ CML cells relative to normal cells after serum deprivation or radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/125,126\">",
"     125,126",
"    </a>",
"    ]. These observations suggest that the antiapoptotic actions of BCR-ABL1 may be dependent upon cell type; further studies are needed to determine the role of protection from apoptosis in the pathophysiology of CML.",
"   </p>",
"   <p>",
"    The antiapoptotic activity of BCR-ABL1 is poorly understood. BCR-ABL1 blocks programmed cell death upstream of mitochondrial cytochrome c release and caspase activation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/127,128\">",
"     127,128",
"    </a>",
"    ]. Signaling pathways implicated in this survival function include Ras [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/129\">",
"     129",
"    </a>",
"    ], Raf-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/130\">",
"     130",
"    </a>",
"    ], phosphatidylinositol 3-kinase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/131\">",
"     131",
"    </a>",
"    ] and its downstream effector Akt [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/132\">",
"     132",
"    </a>",
"    ], STAT5, Bcl-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/133\">",
"     133",
"    </a>",
"    ] and the related proteins Bcl-xL and MCL-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/134\">",
"     134",
"    </a>",
"    ], and nuclear factor kappa B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/135\">",
"     135",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In normal cells, the anti-apoptotic protein Bcl-xL sequesters and inhibits the function of the pro-apoptotic Bcl-2 family members, including Bax and Bak. DNA damage triggers the nonenzymatic deamidation of Bcl-xL, thereby reducing its ability to control",
"    <span class=\"nowrap\">",
"     Bax/Bak",
"    </span>",
"    activity and leading to apoptosis. However, the Bcl-xL deamidation pathway is inhibited in the myeloid cells of patients with CML and polycythemia vera [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/134\">",
"     134",
"    </a>",
"    ]. This results in a blunted apoptotic response to DNA damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2788939\">",
"    <span class=\"h2\">",
"     Altered interaction with the cellular matrix",
"    </span>",
"    &nbsp;&mdash;&nbsp;CML cells have an altered cytoskeleton and decreased adhesion to microenvironmental substrates resulting in the inappropriate expansion of the myeloid cell compartment. However, some of the observed effects in cultured cells are paradoxical. As an example, BCR-ABL1 appears to stimulate rather than impair cell adhesion in cell lines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/136\">",
"     136",
"    </a>",
"    ]. The role of BCR-ABL1-induced abnormalities in the cell cytoskeleton and adhesion in Ph-positive leukemogenesis requires further study.",
"   </p>",
"   <p>",
"    BCR-ABL1 binds to F-actin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/59\">",
"     59",
"    </a>",
"    ] and induces tyrosine phosphorylation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    activation of several proteins associated with cytoskeletal structure and function. These include the GTP-binding protein Rac [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/137\">",
"     137",
"    </a>",
"    ], the adapter proteins Crkl [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/138,139\">",
"     138,139",
"    </a>",
"    ] and p62Dok [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/140\">",
"     140",
"    </a>",
"    ], the scaffolding proteins Hef-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/141\">",
"     141",
"    </a>",
"    ] and Cas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/142\">",
"     142",
"    </a>",
"    ], the Cbl proto-oncoprotein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/143\">",
"     143",
"    </a>",
"    ], and the focal adhesion proteins paxillin, vinculin, tensin, and focal adhesion kinase (FAK) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/144\">",
"     144",
"    </a>",
"    ]. In cultured cells, BCR-ABL1 expression induces multiple abnormalities of cytoskeletal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/145\">",
"     145",
"    </a>",
"    ], cell adhesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/136\">",
"     136",
"    </a>",
"    ] and",
"    <span class=\"nowrap\">",
"     chemotaxis/motility",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/146\">",
"     146",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primitive Philadelphia chromosome positive (Ph+) hematopoietic progenitors from patients with CML show decreased adherence to bone marrow stroma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/147\">",
"     147",
"    </a>",
"    ] and fibronectin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/148\">",
"     148",
"    </a>",
"    ] due to a defect in beta-1 integrin function. Treatment with interferon-alpha [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/149-151\">",
"     149-151",
"    </a>",
"    ], antisense oligodeoxynucleotides to BCR-ABL1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/152\">",
"     152",
"    </a>",
"    ], or BCR-ABL1 tyrosine kinase inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/153\">",
"     153",
"    </a>",
"    ] all increase the adherence of CML progenitors to stroma or fibronectin and restore normal adhesion-dependent inhibition of proliferation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/154\">",
"     154",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Defects in adherence may in part account for the increased circulation and unregulated proliferation of Ph+",
"    <span class=\"nowrap\">",
"     progenitor/stem",
"    </span>",
"    cells in CML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/155\">",
"     155",
"    </a>",
"    ]. Defective adherence may also explain the tendency of Ph+ progenitors to be lost from long-term marrow cultures in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/156\">",
"     156",
"    </a>",
"    ], a phenomenon that has been exploited to purge CML marrow of malignant cells prior to autografting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/157\">",
"     157",
"    </a>",
"    ]. However, restoration of adherence of CML progenitors by interferon-alpha occurs within 48 hours in vitro, but does not explain the prolonged duration of therapy (weeks to months) required for hematologic responses to interferon-alpha in patients with CML. Similarly, it is not clear whether patients who fail to respond to interferon-alpha are also deficient in adhesion responses in vitro. Thus, the relevance of these adhesion defects to the pathophysiology of CML requires further investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7228199\">",
"    <span class=\"h1\">",
"     PROGRESSION TO ACUTE PHASE CML",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, CML usually progresses from a relatively indolent disease (termed chronic phase), easily controlled with oral chemotherapy, to a more aggressive disorder (accelerated phase), during which time disease control is more difficult to achieve. This transition from chronic phase to accelerated phase is often subtle and may not be easily detected. In virtually all patients treated with palliative chemotherapeutic agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    ) and in some patients treated with tyrosine kinase inhibitors, the disease culminates in an acute leukemia, termed \"blast crisis.\" This phase, which is generally refractory to treatment, occurs approximately three to five years after the diagnosis of CML and 18 months after the onset of the accelerated phase. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/16/41225?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the treatment of chronic myeloid leukemia\", section on 'Disease phase'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The progression of CML from chronic phase to accelerated phase or blast crisis is a complex, multistep process that is only partially understood. While some steps in this pathway have been elucidated, many remain unknown. Research into the mechanism of progression has been limited by a lack of animal models that demonstrate a long chronic phase of CML-like disease that transforms into an acute phase. While the Ph chromosome translocation may be the initiating event in CML, progression to blast crisis appears to require the acquisition of other chromosomal changes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dysregulation of differentiation-regulatory genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/2,158,159\">",
"     2,158,159",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following events appear to be necessary for the transformation of chronic phase CML into an acute phase of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/160\">",
"     160",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Constitutive expression of the BCR-ABL1 tyrosine kinase (see",
"      <a class=\"local\" href=\"#H4594144\">",
"       'BCR-ABL1 activity'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Differentiation arrest (see",
"      <a class=\"local\" href=\"#H4594151\">",
"       'Differentiation arrest'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Genetic instability and additional chromosomal abnormalities (see",
"      <a class=\"local\" href=\"#H7228376\">",
"       'Genetic instability'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Inactivation of tumor suppressor genes (see",
"      <a class=\"local\" href=\"#H4594219\">",
"       'Inactivation of tumor suppressor genes'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In accelerated phase and blast crisis of CML, bone marrow granulocyte-macrophage progenitors (GMP) acquire self-renewal properties in vitro and exhibit increased expression, nuclear localization, and function of beta-catenin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/12\">",
"     12",
"    </a>",
"    ], a transcription factor in the Wnt signaling pathway that has been implicated in self-renewal of normal HSCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/17\">",
"     17",
"    </a>",
"    ]. This suggests that aberrant activation of the Wnt pathway may be a central feature of disease progression in CML. Additional studies indicate that the Hedgehog (Hh) signaling pathway may also contribute to self-renewal of CML stem cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/161\">",
"     161",
"    </a>",
"    ]. Together, these observations offer new opportunities for therapeutic intervention in CML through inhibition of the Wnt and Hh signaling.",
"   </p>",
"   <p>",
"    The relationship of beta-catenin-expressing GMP to the leukemic stem cells in CML myeloid blast crisis and the role of Wnt signaling in lymphoid blast crisis have not yet been defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4594144\">",
"    <span class=\"h2\">",
"     BCR-ABL1 activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progression from chronic phase CML to accelerated phase or blast crisis requires the constitutive expression of the BCR-ABL1 protein. Quantitative analyses have supported the hypothesis that this progression may be induced by a rise in BCR-ABL1 activity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tumor samples from advanced disease demonstrate higher levels of the BCR-ABL1 mRNA and protein than that seen in chronic phase disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/162-164\">",
"       162-164",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is a dose-dependent relationship for many of the leukemogenic effects of BCR-ABL1 on cells including uncontrolled proliferation and escape from apoptosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/164,165\">",
"       164,165",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cell lines expressing high levels of BCR-ABL1 induce tumors more rapidly than those that have low levels of expression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/164\">",
"       164",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is unclear if this increase in protein is due to an increase in production of BCR-ABL1, a decrease in protein degradation, or a combination of the two. In advanced CML and myeloid blast crisis, increased expression of the SET protein, an inhibitor of protein phosphatase 2A (PP2A), leads to decreased activity of PP2A and a corresponding increase in BCR-ABL1 signaling through tyrosine phosphorylation. Pharmacologic agents that reactivate PP2A decrease proliferation and survival of CML blast crisis cell lines and primary patient samples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/166\">",
"     166",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4594151\">",
"    <span class=\"h2\">",
"     Differentiation arrest",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blast crisis in CML is characterized by a shift in the level of tumor differentiation to more immature forms. This failure of differentiation may be mediated through interactions between BCR-ABL1 and transcription factors or through a second genetic insult forming a dominant-negative transcription factor:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The transcription factor",
"      <span class=\"nowrap\">",
"       C/EBPalpha",
"      </span>",
"      is required for myeloid differentiation, and dominant-negative mutations in",
"      <span class=\"nowrap\">",
"       C/EBPalpha",
"      </span>",
"      are found in a subset of AML patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/167\">",
"       167",
"      </a>",
"      ]. Expression of",
"      <span class=\"nowrap\">",
"       C/EBPalpha",
"      </span>",
"      is suppressed in blasts from patients with CML myeloid blast crisis, which could contribute to impaired myeloid differentiation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/168,169\">",
"       168,169",
"      </a>",
"      ]. The mechanism may involve binding of",
"      <span class=\"nowrap\">",
"       C/EBPalpha",
"      </span>",
"      mRNA by the poly(rC)-binding protein hnRNPE2, with inhibition of translation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36730?source=see_link&amp;anchor=H14#H14\">",
"       \"Prognosis of acute myeloid leukemia\", section on 'CEBPA gene'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Deletions of the Ikaros (IKZF1) gene are detected in more than 80 percent of Ph-positive B-ALL, including lymphoid blast crisis of CML [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/170,171\">",
"       170,171",
"      </a>",
"      ]. Ikaros is a zinc-finger transcription factor required for normal lymphoid development, and these results suggest that loss of Ikaros function may contribute to the block in lymphoid differentiation characteristic of Ph-positive B-ALL. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/25/22938?source=see_link&amp;anchor=H351299836#H351299836\">",
"       \"Cytogenetics in acute lymphoblastic leukemia\", section on 't(11q23) and&nbsp;ALL in infants'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A subset of patients with myeloid blast crisis acquire a t(3;21) translocation associated with fusion of AML1 and EVI1 transcription factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/172,173\">",
"       172,173",
"      </a>",
"      ]. The leukemogenicity of the fusion gene has been demonstrated by expressing the gene in bone marrow cells; transplanting these cells into mice leads to the development of acute myeloid leukemia 5 to 13 months later [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/174\">",
"       174",
"      </a>",
"      ]. Co-expression of BCR-ABL1 and the AML1-EVI1 fusion protein in mouse bone marrow causes fatal hematologic disease in recipients by four months, with evidence of impaired myeloid differentiation, supporting a cooperating role between BCR-ABL1 and oncogenic transcription factors in progression to myeloid blast crisis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/175\">",
"       175",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25882?source=see_link&amp;anchor=H25#H25\">",
"       \"Molecular genetics of acute myeloid leukemia\", section on 'NUP98/HOXA9 in t(7;11) and NUP98/DDX10 in inv(11)'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25882?source=see_link&amp;anchor=H11#H11\">",
"       \"Molecular genetics of acute myeloid leukemia\", section on 'AML1/EAP, MDS1, EVI1 in t(3;21)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7228376\">",
"    <span class=\"h2\">",
"     Genetic instability",
"    </span>",
"    &nbsp;&mdash;&nbsp;The malignant clone in CML is genetically unstable and acquires multiple genetic abnormalities during the progression from chronic phase to blast crisis. Studies in BCR-ABL1-expressing cell lines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/176\">",
"     176",
"    </a>",
"    ] and BCR-ABL1 transgenic mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/177\">",
"     177",
"    </a>",
"    ] have suggested that BCR-ABL1 may directly induce karyotypic instability. An increased frequency of point mutations is also observed in BCR-ABL1-expressing cell lines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/178\">",
"     178",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Mouse models of CML'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The mechanism of the putative BCR-ABL1-induced genetic instability is unknown. It may be related to an observed accentuation in cell cycle arrest at a",
"    <span class=\"nowrap\">",
"     G2/M",
"    </span>",
"    checkpoint in BCR-ABL1-expressing cells in response to genotoxic damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/124,179\">",
"     124,179",
"    </a>",
"    ], possibly via activation of STAT5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/180\">",
"     180",
"    </a>",
"    ]. Increased homologous recombination mediated by Rad51 family members may also contribute to genetic instability and drug resistance in BCR-ABL1-expressing cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/181\">",
"     181",
"    </a>",
"    ]. BCR-ABL1 expression stimulates the production of reactive oxygen species (ROS) in hematopoietic progenitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/182\">",
"     182",
"    </a>",
"    ], and other studies suggest that ROS may contribute to the increased level of DNA damage and double-strand DNA breaks in BCR-ABL1-expressing cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/183\">",
"     183",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional cytogenetic abnormalities develop in over 80 percent of patients with CML in accelerated and blast crisis phases, most commonly trisomy 8, trisomy 19, duplication of the Ph chromosome, and isochromosome 17q. At least some of these cytogenetic abnormalities have been characterized at the molecular level. (See",
"    <a class=\"local\" href=\"#H4594219\">",
"     'Inactivation of tumor suppressor genes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other cytogenetic abnormalities and abnormalities in gene expression have been noted but require further characterization:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mutations in two distinct RNA-binding proteins, Lin28 and Musashi, may contribute to CML disease progression in some patients. Further studies are necessary to elucidate the molecular mechanisms involved in each case.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Lin28 and the related protein Lin28B act by suppressing the maturation of miRNA let-7, which in turn may negatively regulate several signaling pathways in hematopoietic cells. Lin28 overexpression is observed in blast crisis CML and several other cancers, and is associated with a poor prognosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/184\">",
"       184",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Musashi family protein MSI2, an RNA-binding protein that interferes with translation of target mRNAs and functions in cell fate determination during embryogenesis, is also overexpressed in advanced CML and acute myeloid leukemia, and is likewise associated with poor survival [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/185,186\">",
"       185,186",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormalities of DNA methylation have also been observed in CML disease progression, including methylation of the calcitonin gene, the M-bcr region, and the c-ABL1 promoter region. In theory, CML patients might be monitored molecularly for evidence of disease progression, but this approach has not been successfully utilized clinically to date.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4594219\">",
"    <span class=\"h2\">",
"     Inactivation of tumor suppressor genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some cases of CML that have progressed to blast crisis demonstrate loss of tumor suppressor genes. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twenty to 30 percent of patients with myeloid blast crisis have alterations (deletions and rearrangements) in the p53 tumor suppressor gene on chromosome 17p13 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/187\">",
"       187",
"      </a>",
"      ], although there may also be another tumor suppressor gene on 17p that is involved in disease progression. Direct support for a role of p53 comes from a transgenic animal model of p210BCR-ABL1 in which the loss of p53 was associated with initial signs resembling CML, followed by more rapid proliferation of blast cells and early death when compared with p210BCR-ABL1 mice with no abnormality in p53 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/188\">",
"       188",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Amplification of c-MYC (on chromosome 8) and deletion of the RB1 or",
"      <span class=\"nowrap\">",
"       p16INK4A/p14ARF",
"      </span>",
"      (CDKN2A) tumor suppressor genes is more common in lymphoid blast crisis. Genetic studies in mouse model systems suggest that loss of the p19ARF tumor suppressor gene contributes directly to the transformation of immature B-lymphoid cells by v-Abl and BCR-ABL1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/189-191\">",
"       189-191",
"      </a>",
"      ]. Deletion of CDKN2A or the closely linked CDKN2B gene on chromosome 9p21 is frequent during progression of Ph",
"      <sup>",
"       +",
"      </sup>",
"      B-ALL and is a poor prognostic factor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/192\">",
"       192",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Large deletions of the derivative chromosome 9 are found in 15 to 20 percent of patients with chronic phase CML, appear to occur at the time of the Ph translocation, and are associated with decreased survival due to more rapid disease progression that is independent of other clinical features [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/193\">",
"       193",
"      </a>",
"      ]. The mechanism is thought to involve deletion of one or more tumor suppressor genes adjacent to 9q34.1. Lack of expression of the reciprocal ABL1-BCR fusion gene is observed in a similar proportion of CML patients but does not correlate with deletions of der9q or with survival [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/194\">",
"       194",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MOUSE MODELS OF CML",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a great deal has been learned about the transforming and signaling properties of BCR-ABL1 from studies in cultured cells, these systems do not model the complex physiology of the bone marrow. A complete understanding of Ph-positive leukemia requires expression of the BCR-ABL1 oncogene within the context of the hematopoietic system. The inbred laboratory mouse has been the species of choice for these efforts, which have focused on complementary methods for expression of BCR-ABL1 in the blood system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/195\">",
"     195",
"    </a>",
"    ]. There are three main methods of developing mouse models for CML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/85\">",
"     85",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Retroviral transduction of murine bone marrow ex vivo followed by transplantation",
"     </li>",
"     <li>",
"      Generation of transgenic strains of mice",
"     </li>",
"     <li>",
"      Xenograft non-obese dynamic severe combined immunodeficient",
"      <span class=\"nowrap\">",
"       (NOD/SCID)",
"      </span>",
"      mouse",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As yet there is no mouse model that provides a long chronic phase of CML-like disease followed by transformation to a blast crisis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Retroviral transduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The retroviral transduction mouse model was first introduced in the 1990s and has evolved to become the most frequently used in vivo model of CML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/56,196-200\">",
"     56,196-200",
"    </a>",
"    ]. A donor mouse is treated with 5-fluorouracil and bone marrow is collected. This donor bone marrow is exposed ex vivo to a BCR-ABL1 transducing retrovirus and then transplanted into a lethally irradiated syngeneic recipient mouse. Recipients develop a number of distinct hematologic malignancies, including a myeloproliferative disease closely resembling human CML, and B-lymphoid leukemia similar to Ph-positive acute lymphoblastic leukemia.",
"   </p>",
"   <p>",
"    The CML-like disease induced in mice by BCR-ABL1 is a very close pathophysiologic match to human CML:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The target cell for retroviral transduction that gives rise to CML-like disease is an early",
"      <span class=\"nowrap\">",
"       progenitor/stem",
"      </span>",
"      cell with multilineage repopulating ability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recipient mice demonstrate splenomegaly, increased numbers of mature granulocytes circulating in the peripheral blood that express BCR-ABL, and bone marrow invasion by leukemic stem cells and progenitor cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      This CML-like disease is transplantable and undergoes evolution to acute leukemia, resembling blast crisis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/201,202\">",
"       201,202",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This model has provided support for BCR-ABL1 as the principal cause of these malignancies and has allowed for the in vivo study of BCR-ABL1 signaling, identification of novel genes involved in CML development, and testing of potential therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/8,203,204\">",
"     8,203,204",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evolution to myeloid blast crisis can be mediated by the aberrant expression of several transcription factors, including NUP98-HOXA9, which is the product of a t(7;11) chromosomal translocation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/172\">",
"     172",
"    </a>",
"    ]. A murine model of CML blast crisis can be induced by interactions between",
"    <span class=\"nowrap\">",
"     BCR/ABL",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     NUP98/HOXA9",
"    </span>",
"    and the transcriptional repressor hairy enhancer of split 1 (Hes1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/205\">",
"     205",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Improvements in the generation of high titer retroviral stocks have permitted efficient induction of CML-like disease in mice, allowing the system to be used as an assay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/56,199,200\">",
"     56,199,200",
"    </a>",
"    ]. A direct comparison of the leukemogenic properties of the p190, p210, and p230 BCR-ABL1 oncogenes in this model system indicates that all three forms of BCR-ABL1 induce a similar CML-like disease with equal efficiency, but that p190 is more potent than either p210 or p230 for lymphoid leukemogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/56\">",
"     56",
"    </a>",
"    ]. These results suggest that the rarity of p190 in human chronic phase CML is due to infrequent BCR intron 1 breakpoints during the genesis of the Ph chromosome in stem cells; they do not support the hypothesis that p230 BCR-ABL1 induces a milder form of CML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/206\">",
"     206",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Donor bone marrow from mice with targeted mutations in signaling molecules can be used to test the role of a given pathway in BCR-ABL1 leukemogenesis. Although human CML progenitors express aberrant transcripts for IL-3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/117\">",
"     117",
"    </a>",
"    ], bone marrow from mice with homozygous inactivation of the IL-3 gene can induce CML-like disease after transduction with BCR-ABL1 and transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/118\">",
"     118",
"    </a>",
"    ], suggesting IL-3 is not required for the development of CML.",
"   </p>",
"   <p>",
"    Although Src family kinases are activated by BCR-ABL1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/207\">",
"     207",
"    </a>",
"    ], BCR-ABL1 can efficiently induce CML-like leukemia in bone marrow from mice lacking Lyn, Hck, and Fgr, the three principal Src kinases expressed in myeloid progenitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/208\">",
"     208",
"    </a>",
"    ]. However, induction of B-lymphoid leukemia by BCR-ABL1 is attenuated by the lack of these three Src kinases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/208\">",
"     208",
"    </a>",
"    ]. These results suggest that Src family kinases may be rational therapeutic targets in Ph+ B-ALL and CML lymphoid blast crisis, but not in chronic phase CML. In agreement with this suggestion, siRNA knockdown of Lyn impaired survival in cells from CML lymphoid blast crisis patients to a greater extent than in myeloid cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/209\">",
"     209",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The transcription factor STAT5 has also been implicated as an essential factor in the pathogenesis of BCR-ABL1-induced CML-like leukemia. Evidence for this role of STAT5 primarily comes from in vivo models that have demonstrated that CML-like leukemia cannot be induced in recipients of bone marrow from STAT5 mutant donors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/210\">",
"     210",
"    </a>",
"    ], although STAT5 may not be required for maintenance of CML stem cells or progression to blast crisis in this model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/211\">",
"     211",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2788925\">",
"     'Uncontrolled proliferation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Future use of this model system should provide a platform for drug testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/212\">",
"     212",
"    </a>",
"    ] and investigation of immunological therapy of CML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/213,214\">",
"     213,214",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6496550\">",
"    <span class=\"h2\">",
"     Transgenic models",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of transgenic mouse models of CML was initially thwarted by findings that the constitutive tyrosine kinase activity of the BCR-ABL1 gene product caused toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/215\">",
"     215",
"    </a>",
"    ] and embryonic lethality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/216\">",
"     216",
"    </a>",
"    ] in transgenic mice. Embryonic lethality was overcome by the use of minimally active promoters, particularly the metallothionein promoter or a tet-off (with expression controlled by tetracycline administration) system, to control the timing of BCR-ABL1 expression. This has allowed the development of transgenic mice expressing the p190 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/217\">",
"     217",
"    </a>",
"    ] and p210 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/218,219\">",
"     218,219",
"    </a>",
"    ] forms of BCR-ABL1. Despite wide expression of the transgene in both bone marrow and non-hematopoietic tissues, these mice exclusively develop acute lymphoid malignancies, demonstrating that BCR-ABL1 is a leukemia-specific oncogene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/220,221\">",
"     220,221",
"    </a>",
"    ]. Subsequently, the conditional expression of BCR-ABL1 in hematopoietic stem cells has resulted in a CML-like myeloproliferative disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/222\">",
"     222",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Breeding BCR-ABL1 transgene into a",
"    <em>",
"     Bcr",
"    </em>",
"    null background has demonstrated that lymphoid leukemogenesis by BCR-ABL1 does not require the normal BCR gene product [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/223,224\">",
"     223,224",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'BCR'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Characterization of transgenic mice before the development of overt leukemia has demonstrated early karyotypic instability in lymphoid cells, suggesting genetic instability is a primary consequence of BCR-ABL1 expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/177\">",
"     177",
"    </a>",
"    ]. Comparison of the leukemogenic properties of the p190 and p210 forms of BCR-ABL1 in transgenic mice indicate that p210 mice develop B- and T-lymphoid leukemia of relatively long latency, while p190 mice develop exclusively B-lymphoid malignancy of shorter latency, supporting a distinct difference in lymphoid leukemogenesis by the two isoforms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/218\">",
"     218",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conditional transgenic models of BCR-ABL1 have been developed that allow control of oncogene expression. In one model, conditional expression of BCR-ABL1 in lymphoid progenitors results in acute B-lymphoblastic leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/221\">",
"     221",
"    </a>",
"    ]. Complete remission of leukemia was achieved by suppression of BCR-ABL1 expression, even after multiple rounds of induction and reversion. In addition, BCR-ABL1 has a profound antiapoptotic effect on primary malignant B-lymphoid cells in vivo. In a more recent model, conditional expression of BCR-ABL1 in hematopoietic stem cells results in CML-like myeloproliferative disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/222\">",
"     222",
"    </a>",
"    ]. Both models have shown that continuous expression of BCR-ABL1 is required for maintenance of the leukemic phenotype in vivo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/221,222\">",
"     221,222",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6496345\">",
"    <span class=\"h2\">",
"     Xenograft NOD/SCID model",
"    </span>",
"    &nbsp;&mdash;&nbsp;The human xenograft non-obese dynamic severe combined immunodeficient",
"    <span class=\"nowrap\">",
"     (NOD/SCID)",
"    </span>",
"    mouse model is a newer technique that may offer an environment more representative of the physiologic state of CML in humans. CD34+ cells are purified from the peripheral blood or bone marrow of patients with CML and transplanted into sublethally irradiated",
"    <span class=\"nowrap\">",
"     NOD/SCID",
"    </span>",
"    mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/225,226\">",
"     225,226",
"    </a>",
"    ]. Both normal and leukemic cells are found in the bone marrow of the recipient mice. Although most recipient mice do not develop lethal CML-like disease, transplantation of cells from blast crisis results in the rapid increase in leukemic cells in the recipient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/33/40474/abstract/225\">",
"     225",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/60/37829?source=see_link\">",
"       \"Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6495922\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm derived from an abnormal pluripotent hematopoietic stem cell that has acquired the BCR-ABL1 fusion gene, usually through t(9;22)(q34;q11), also known as the Philadelphia chromosome. (See",
"      <a class=\"local\" href=\"#H6496975\">",
"       'Cell of origin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All leukemias, including CML, appear to be maintained by a pool of self-renewing malignant cells called leukemic stem cells (LSC). CML LSC may be more immature than the majority of circulating leukemic cells, and are thought to have originated from cells with existing self-renewal capacity or from progenitors that have re-acquired this stem cell-like property. (See",
"      <a class=\"local\" href=\"#H2791988\">",
"       'The leukemia stem cell'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The development of chronic phase CML appears to be a direct result of BCR-ABL1 activity, which promotes its development by allowing:",
"     </li>",
"     <li>",
"      Uncontrolled proliferation of transformed cells (see",
"      <a class=\"local\" href=\"#H2788925\">",
"       'Uncontrolled proliferation'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Discordant maturation (see",
"      <a class=\"local\" href=\"#H2793233\">",
"       'Discordant maturation'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Escape from apoptosis (see",
"      <a class=\"local\" href=\"#H2788932\">",
"       'Escape from apoptosis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Altered interaction with the cellular matrix (see",
"      <a class=\"local\" href=\"#H2788939\">",
"       'Altered interaction with the cellular matrix'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The progression of CML from chronic phase to accelerated phase or blast crisis is a complex, multistep process that is only partially understood. The following events appear to be necessary for the transformation of chronic phase CML into an acute phase of disease:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Constitutive expression of the BCR-ABL1 tyrosine kinase (see",
"      <a class=\"local\" href=\"#H4594144\">",
"       'BCR-ABL1 activity'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Differentiation arrest (see",
"      <a class=\"local\" href=\"#H4594151\">",
"       'Differentiation arrest'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Genetic instability and additional chromosomal abnormalities (see",
"      <a class=\"local\" href=\"#H7228376\">",
"       'Genetic instability'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Inactivation of tumor suppressor genes (see",
"      <a class=\"local\" href=\"#H4594219\">",
"       'Inactivation of tumor suppressor genes'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mouse models have provided support for BCR-ABL1 as the principal cause of these malignancies and have allowed for the in vivo study of BCR-ABL1 signaling, identification of novel genes involved in CML development, and testing of potential therapies. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Mouse models of CML'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/1\">",
"      Verfaillie CM. Biology of chronic myelogenous leukemia. Hematol Oncol Clin North Am 1998; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/2\">",
"      Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341:164.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/4\">",
"      Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 1977; 63:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/5\">",
"      Gilliland DG, Blanchard KL, Levy J, et al. Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction. Proc Natl Acad Sci U S A 1991; 88:6848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/6\">",
"      WHANG J, FREI E 3rd, TJIO JH, et al. THE DISTRIBUTION OF THE PHILADELPHIA CHROMOSOME IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA. Blood 1963; 22:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/7\">",
"      Maguer-Satta V, Petzer AL, Eaves AC, Eaves CJ. BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia. Blood 1996; 88:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/8\">",
"      Hu Y, Swerdlow S, Duffy TM, et al. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci U S A 2006; 103:16870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/9\">",
"      Haferlach T, Winkemann M, Nickenig C, et al. Which compartments are involved in Philadelphia-chromosome positive chronic myeloid leukaemia? An answer at the single cell level by combining May-Gr&uuml;nwald-Giemsa staining and fluorescence in situ hybridization techniques. Br J Haematol 1997; 97:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/10\">",
"      Allouche M, Bourinbaiar A, Georgoulias V, et al. T cell lineage involvement in lymphoid blast crisis of chronic myeloid leukemia. Blood 1985; 66:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/11\">",
"      Falini B, Tabilio A, Pelicci PG, et al. T-cell receptor beta-chain gene rearrangement in a case of Ph1-positive chronic myeloid leukemia blast crisis. Br J Haematol 1986; 62:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/12\">",
"      Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/13\">",
"      Minami Y, Stuart SA, Ikawa T, et al. BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc Natl Acad Sci U S A 2008; 105:17967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/14\">",
"      Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/15\">",
"      Passegu&eacute; E, Jamieson CH, Ailles LE, Weissman IL. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci U S A 2003; 100 Suppl 1:11842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/16\">",
"      Park CY, Tseng D, Weissman IL. Cancer stem cell-directed therapies: recent data from the laboratory and clinic. Mol Ther 2009; 17:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/17\">",
"      Reya T, Duncan AW, Ailles L, et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003; 423:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/18\">",
"      Huntly BJ, Shigematsu H, Deguchi K, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004; 6:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/19\">",
"      Perl A, Carroll M. BCR-ABL kinase is dead; long live the CML stem cell. J Clin Invest 2011; 121:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/20\">",
"      Corbin AS, Agarwal A, Loriaux M, et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011; 121:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/21\">",
"      Chu S, McDonald T, Lin A, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 2011; 118:5565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/22\">",
"      Kumari A, Brendel C, Hochhaus A, et al. Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood 2012; 119:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/23\">",
"      Hamilton A, Helgason GV, Schemionek M, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 2012; 119:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/24\">",
"      Zhang H, Peng C, Hu Y, et al. The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells. Nat Genet 2012; 44:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/25\">",
"      Stein AM, Bottino D, Modur V, et al. BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment. Clin Cancer Res 2011; 17:6812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/26\">",
"      Tang M, Gonen M, Quintas-Cardama A, et al. Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood 2011; 118:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/27\">",
"      Smith CC, Shah NP. Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia. Clin Cancer Res 2011; 17:6605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/28\">",
"      Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96:3343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/29\">",
"      Holyoake DT. Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory. Br J Haematol 2001; 113:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/30\">",
"      Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 2003; 138:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/31\">",
"      Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/32\">",
"      McWhirter JR, Galasso DL, Wang JY. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 1993; 13:7587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/33\">",
"      Maru Y, Witte ON. The BCR gene encodes a novel serine/threonine kinase activity within a single exon. Cell 1991; 67:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/34\">",
"      Chuang TH, Xu X, Kaartinen V, et al. Abr and Bcr are multifunctional regulators of the Rho GTP-binding protein family. Proc Natl Acad Sci U S A 1995; 92:10282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/35\">",
"      Diekmann D, Brill S, Garrett MD, et al. Bcr encodes a GTPase-activating protein for p21rac. Nature 1991; 351:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/36\">",
"      Voncken JW, van Schaick H, Kaartinen V, et al. Increased neutrophil respiratory burst in bcr-null mutants. Cell 1995; 80:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/37\">",
"      Jackson P, Baltimore D. N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl. EMBO J 1989; 8:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/38\">",
"      Van Etten RA. Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends Cell Biol 1999; 9:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/39\">",
"      Van Etten RA, Jackson P, Baltimore D. The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell 1989; 58:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/40\">",
"      Van Etten RA, Jackson PK, Baltimore D, et al. The COOH terminus of the c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity. J Cell Biol 1994; 124:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/41\">",
"      Kharbanda S, Ren R, Pandey P, et al. Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature 1995; 376:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/42\">",
"      Wen ST, Van Etten RA. The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev 1997; 11:2456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/43\">",
"      Lewis JM, Baskaran R, Taagepera S, et al. Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. Proc Natl Acad Sci U S A 1996; 93:15174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/44\">",
"      Plattner R, Kadlec L, DeMali KA, et al. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev 1999; 13:2400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/45\">",
"      Baskaran R, Wood LD, Whitaker LL, et al. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 1997; 387:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/46\">",
"      Brasher BB, Van Etten RA. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J Biol Chem 2000; 275:35631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/47\">",
"      Pluk H, Dorey K, Superti-Furga G. Autoinhibition of c-Abl. Cell 2002; 108:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/48\">",
"      Pendergast AM, Muller AJ, Havlik MH, et al. Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor. Proc Natl Acad Sci U S A 1991; 88:5927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/49\">",
"      Tybulewicz VL, Crawford CE, Jackson PK, et al. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 1991; 65:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/50\">",
"      Schwartzberg PL, Stall AM, Hardin JD, et al. Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations. Cell 1991; 65:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/51\">",
"      Hardin JD, Boast S, Schwartzberg PL, et al. Bone marrow B lymphocyte development in c-abl-deficient mice. Cell Immunol 1995; 165:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/52\">",
"      Kharbanda S, Pandey P, Morris PL, et al. Functional role for the c-Abl tyrosine kinase in meiosis I. Oncogene 1998; 16:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/53\">",
"      Pane F, Frigeri F, Sindona M, et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 1996; 88:2410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/54\">",
"      Konopka JB, Watanabe SM, Witte ON. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984; 37:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/55\">",
"      Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/56\">",
"      Li S, Ilaria RL Jr, Million RP, et al. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999; 189:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/57\">",
"      Pendergast AM, Muller AJ, Havlik MH, et al. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell 1991; 66:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/58\">",
"      Wetzler M, Talpaz M, Van Etten RA, et al. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest 1993; 92:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/59\">",
"      McWhirter JR, Wang JY. An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J 1993; 12:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/60\">",
"      Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001; 7:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/61\">",
"      Eaves AC, Barnett MJ, Ponchio L, et al. Differences between normal and CML stem cells: potential targets for clinical exploitation. Stem Cells 1998; 16 Suppl 1:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/62\">",
"      Strife A, Lambek C, Wisniewski D, et al. Discordant maturation as the primary biological defect in chronic myelogenous leukemia. Cancer Res 1988; 48:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/63\">",
"      Fialkow PJ, Martin PJ, Najfeld V, et al. Evidence for a multistep pathogenesis of chronic myelogenous leukemia. Blood 1981; 58:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/64\">",
"      Delforge M, Boogaerts MA, McGlave PB, Verfaillie CM. BCR/ABL- CD34(+)HLA-DR- progenitor cells in early chronic phase, but not in more advanced phases, of chronic myelogenous leukemia are polyclonal. Blood 1999; 93:284.",
"     </a>",
"    </li>",
"    <li>",
"     Van Etten RA. Malignant transformation by abl and BCR/ABL. In: Oncogenes and Tumor Suppressor Genes in Human Malignancies, Benz CC, Liu ET (Eds), Kluwer Academic Publishers, Norwood, MA 1992. p.167.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/66\">",
"      Scherle PA, Dorshkind K, Witte ON. Clonal lymphoid progenitor cell lines expressing the BCR/ABL oncogene retain full differentiative function. Proc Natl Acad Sci U S A 1990; 87:1908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/67\">",
"      LANGE RD, MOLONEY WC, YAMAWAKI T. Leukemia in atomic bomb survivors. I. General observations. Blood 1954; 9:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/68\">",
"      Berman E, Strife A, Wisniewski D, et al. Duration of the preclinical phase of chronic myelogenous leukemia: a case report. Blood 1991; 78:2969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/69\">",
"      Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci U S A 1988; 85:9312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/70\">",
"      Hariharan IK, Adams JM, Cory S. bcr-abl oncogene renders myeloid cell line factor independent: potential autocrine mechanism in chronic myeloid leukemia. Oncogene Res 1988; 3:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/71\">",
"      Sirard C, Laneuville P, Dick JE. Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism. Blood 1994; 83:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/72\">",
"      McLaughlin J, Chianese E, Witte ON. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci U S A 1987; 84:6558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/73\">",
"      McLaughlin J, Chianese E, Witte ON. Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. Mol Cell Biol 1989; 9:1866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/74\">",
"      Schuster C, Forster K, Dierks H, et al. The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate. Blood 2003; 101:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/75\">",
"      Pendergast AM, Gishizky ML, Havlik MH, Witte ON. SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence. Mol Cell Biol 1993; 13:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/76\">",
"      Carlesso N, Griffin JD, Druker BJ. Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line. Oncogene 1994; 9:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/77\">",
"      Kabarowski JH, Allen PB, Wiedemann LM. A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells. EMBO J 1994; 13:5887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/78\">",
"      Sawyers CL. Signal transduction pathways involved in BCR-ABL transformation. Baillieres Clin Haematol 1997; 10:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/79\">",
"      Matulonis U, Salgia R, Okuda K, et al. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp Hematol 1993; 21:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/80\">",
"      Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/81\">",
"      Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997; 90:4947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/82\">",
"      Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101:4701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/83\">",
"      Graham SM, J&oslash;rgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/84\">",
"      Pendergast AM, Quilliam LA, Cripe LD, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993; 75:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/85\">",
"      Chen Y, Peng C, Sullivan C, et al. Critical molecular pathways in cancer stem cells of chronic myeloid leukemia. Leukemia 2010; 24:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/86\">",
"      Graham SM, Vass JK, Holyoake TL, Graham GJ. Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources. Stem Cells 2007; 25:3111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/87\">",
"      Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 2006; 103:2794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/88\">",
"      Bruns I, Czibere A, Fischer JC, et al. The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence. Leukemia 2009; 23:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/89\">",
"      Jagani Z, Dorsch M, Warmuth M. Hedgehog pathway activation in chronic myeloid leukemia. Cell Cycle 2010; 9:3449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/90\">",
"      Gregory MA, Phang TL, Neviani P, et al. Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell 2010; 18:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/91\">",
"      Naka K, Hoshii T, Muraguchi T, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010; 463:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/92\">",
"      Ogawa M, Fried J, Sakai Y, et al. Studies of cellular proliferation in human leukemia. VI. The proliferative activity, generation time, and emergence time of neutrophilic granulocytes in chronic granulocytic leukemia. Cancer 1970; 25:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/93\">",
"      Goto T, Nishikori M, Arlin Z, et al. Growth characteristics of leukemic and normal hematopoietic cells in Ph' + chronic myelogenous leukemia and effects of intensive treatment. Blood 1982; 59:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/94\">",
"      Kantarjian HM, Talpaz M, LeMaistre CF, et al. Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia. Cancer 1991; 67:2959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/95\">",
"      Lisker R, Casas L, Mutchinick O, et al. Late-appearing Philadelphia chromosome in two patients with chronic myelogenous leukemia. Blood 1980; 56:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/96\">",
"      Cortez D, Reuther G, Pendergast AM. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene 1997; 15:2333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/97\">",
"      Jonuleit T, Peschel C, Schwab R, et al. Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors. Br J Haematol 1998; 100:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/98\">",
"      Skorski T, Nieborowska-Skorska M, Szczylik C, et al. C-RAF-1 serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis. Cancer Res 1995; 55:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/99\">",
"      Sawyers CL, McLaughlin J, Witte ON. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med 1995; 181:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/100\">",
"      Puil L, Liu J, Gish G, et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 1994; 13:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/101\">",
"      Goga A, McLaughlin J, Afar DE, et al. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell 1995; 82:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/102\">",
"      Peters DG, Hoover RR, Gerlach MJ, et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood 2001; 97:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/103\">",
"      Cortes J, Albitar M, Thomas D, et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2003; 101:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/104\">",
"      Raitano AB, Halpern JR, Hambuch TM, Sawyers CL. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci U S A 1995; 92:11746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/105\">",
"      Dickens M, Rogers JS, Cavanagh J, et al. A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 1997; 277:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/106\">",
"      Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 1996; 183:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/107\">",
"      Shuai K, Halpern J, ten Hoeve J, et al. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996; 13:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/108\">",
"      Ilaria RL Jr, Van Etten RA. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996; 271:31704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/109\">",
"      Wang Y, Cai D, Brendel C, et al. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood 2007; 109:2147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/110\">",
"      de Groot RP, Raaijmakers JA, Lammers JW, et al. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood 1999; 94:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/111\">",
"      Nieborowska-Skorska M, Wasik MA, Slupianek A, et al. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med 1999; 189:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/112\">",
"      Mui AL, Wakao H, Kinoshita T, et al. Suppression of interleukin-3-induced gene expression by a C-terminal truncated Stat5: role of Stat5 in proliferation. EMBO J 1996; 15:2425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/113\">",
"      Ilaria RL Jr, Hawley RG, Van Etten RA. Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation. Blood 1999; 93:4154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/114\">",
"      Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell 1992; 70:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/115\">",
"      Afar DE, McLaughlin J, Sherr CJ, et al. Signaling by ABL oncogenes through cyclin D1. Proc Natl Acad Sci U S A 1995; 92:9540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/116\">",
"      Metcalf D, Moore MA, Sheridan JW, Spitzer G. Responsiveness of human granulocytic leukemic cells to colony-stimulating factor. Blood 1974; 43:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/117\">",
"      Jiang X, Lopez A, Holyoake T, et al. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci U S A 1999; 96:12804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/118\">",
"      Li S, Gillessen S, Tomasson MH, et al. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL. Blood 2001; 97:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/119\">",
"      Cashman JD, Eaves CJ, Sarris AH, Eaves AC. MCP-1, not MIP-1alpha, is the endogenous chemokine that cooperates with TGF-beta to inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures. Blood 1998; 92:2338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/120\">",
"      Clarke MF. Chronic myelogenous leukemia--identifying the hydra's heads. N Engl J Med 2004; 351:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/121\">",
"      ATHENS JW, RAAB SO, HAAB OP, et al. LEUKOKINETIC STUDIES. X. BLOOD GRANULOCYTE KINETICS IN CHRONIC MYELOCYTIC LEUKEMIA. J Clin Invest 1965; 44:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/122\">",
"      McGahon A, Bissonnette R, Schmitt M, et al. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994; 83:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/123\">",
"      Bedi A, Zehnbauer BA, Barber JP, et al. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994; 83:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/124\">",
"      Bedi A, Barber JP, Bedi GC, et al. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 1995; 86:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/125\">",
"      Amos TA, Lewis JL, Grand FH, et al. Apoptosis in chronic myeloid leukaemia: normal responses by progenitor cells to growth factor deprivation, X-irradiation and glucocorticoids. Br J Haematol 1995; 91:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/126\">",
"      Albrecht T, Schwab R, Henkes M, et al. Primary proliferating immature myeloid cells from CML patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal. Br J Haematol 1996; 95:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/127\">",
"      Dubrez L, Eymin B, Sordet O, et al. BCR-ABL delays apoptosis upstream of procaspase-3 activation. Blood 1998; 91:2415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/128\">",
"      Amarante-Mendes GP, Naekyung Kim C, Liu L, et al. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood 1998; 91:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/129\">",
"      Cortez D, Stoica G, Pierce JH, Pendergast AM. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway. Oncogene 1996; 13:2589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/130\">",
"      Salomoni P, Wasik MA, Riedel RF, et al. Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant. J Exp Med 1998; 187:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/131\">",
"      Skorski T, Kanakaraj P, Nieborowska-Skorska M, et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995; 86:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/132\">",
"      Skorski T, Bellacosa A, Nieborowska-Skorska M, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 1997; 16:6151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/133\">",
"      S&aacute;nchez-Garc&iacute;a I, Gr&uuml;tz G. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci U S A 1995; 92:5287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/134\">",
"      Zhao R, Follows GA, Beer PA, et al. Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders. N Engl J Med 2008; 359:2778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/135\">",
"      Reuther JY, Reuther GW, Cortez D, et al. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev 1998; 12:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/136\">",
"      Bazzoni G, Carlesso N, Griffin JD, Hemler ME. Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. J Clin Invest 1996; 98:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/137\">",
"      Skorski T, Wlodarski P, Daheron L, et al. BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac. Proc Natl Acad Sci U S A 1998; 95:11858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/138\">",
"      ten Hoeve J, Arlinghaus RB, Guo JQ, et al. Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia. Blood 1994; 84:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/139\">",
"      Nichols GL, Raines MA, Vera JC, et al. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood 1994; 84:2912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/140\">",
"      Carpino N, Wisniewski D, Strife A, et al. p62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. Cell 1997; 88:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/141\">",
"      de Jong R, van Wijk A, Haataja L, et al. BCR/ABL-induced leukemogenesis causes phosphorylation of Hef1 and its association with Crkl. J Biol Chem 1997; 272:32649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/142\">",
"      Salgia R, Pisick E, Sattler M, et al. p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene. J Biol Chem 1996; 271:25198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/143\">",
"      Sattler M, Salgia R, Okuda K, et al. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway. Oncogene 1996; 12:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/144\">",
"      Salgia R, Brunkhorst B, Pisick E, et al. Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Oncogene 1995; 11:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/145\">",
"      Salgia R, Li JL, Ewaniuk DS, et al. BCR/ABL induces multiple abnormalities of cytoskeletal function. J Clin Invest 1997; 100:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/146\">",
"      Salgia R, Quackenbush E, Lin J, et al. The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. Blood 1999; 94:4233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/147\">",
"      Gordon MY, Dowding CR, Riley GP, et al. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 1987; 328:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/148\">",
"      Verfaillie CM, McCarthy JB, McGlave PB. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J Clin Invest 1992; 90:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/149\">",
"      Dowding C, Guo AP, Osterholz J, et al. Interferon-alpha overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells. Blood 1991; 78:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/150\">",
"      Bhatia R, Wayner EA, McGlave PB, Verfaillie CM. Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function. J Clin Invest 1994; 94:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/151\">",
"      Bhatia R, McCarthy JB, Verfaillie CM. Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Blood 1996; 87:3883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/152\">",
"      Bhatia R, Verfaillie CM. Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores beta1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors. Blood 1998; 91:3414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/153\">",
"      Bhatia R, Munthe HA, Verfaillie CM. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors. Leukemia 1998; 12:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/154\">",
"      Hurley RW, McCarthy JB, Verfaillie CM. Direct adhesion to bone marrow stroma via fibronectin receptors inhibits hematopoietic progenitor proliferation. J Clin Invest 1995; 96:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/155\">",
"      Verfaillie CM, Hurley R, Lundell BI, et al. Integrin-mediated regulation of hematopoiesis: do BCR/ABL-induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors? Acta Haematol 1997; 97:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/156\">",
"      Coulombel L, Kalousek DK, Eaves CJ, et al. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N Engl J Med 1983; 308:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/157\">",
"      Barnett MJ, Eaves CJ, Phillips GL, et al. Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study. Blood 1994; 84:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/158\">",
"      Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004; 103:4010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/159\">",
"      Zhang SJ, Ma LY, Huang QH, et al. Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. Proc Natl Acad Sci U S A 2008; 105:2076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/160\">",
"      Quint&aacute;s-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009; 113:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/161\">",
"      Dierks C, Beigi R, Guo GR, et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008; 14:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/162\">",
"      Gaiger A, Henn T, H&ouml;rth E, et al. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood 1995; 86:2371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/163\">",
"      Guo JQ, Wang JY, Arlinghaus RB. Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients. Cancer Res 1991; 51:3048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/164\">",
"      Barnes DJ, Schultheis B, Adedeji S, Melo JV. Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. Oncogene 2005; 24:6432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/165\">",
"      Cambier N, Chopra R, Strasser A, et al. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. Oncogene 1998; 16:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/166\">",
"      Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005; 8:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/167\">",
"      Pabst T, Mueller BU, Zhang P, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001; 27:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/168\">",
"      Perrotti D, Cesi V, Trotta R, et al. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet 2002; 30:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/169\">",
"      Wagner K, Zhang P, Rosenbauer F, et al. Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy. Proc Natl Acad Sci U S A 2006; 103:6338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/170\">",
"      Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008; 453:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/171\">",
"      Martinelli G, Iacobucci I, Storlazzi CT, et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol 2009; 27:5202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/172\">",
"      Dash AB, Williams IR, Kutok JL, et al. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc Natl Acad Sci U S A 2002; 99:7622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/173\">",
"      Nucifora G, Birn DJ, Espinosa R 3rd, et al. Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis. Blood 1993; 81:2728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/174\">",
"      Cuenco GM, Nucifora G, Ren R. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML. Proc Natl Acad Sci U S A 2000; 97:1760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/175\">",
"      Cuenco GM, Ren R. Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia. Oncogene 2001; 20:8236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/176\">",
"      Laneuville P, Sun G, Timm M, Vekemans M. Clonal evolution in a myeloid cell line transformed to interleukin-3 independent growth by retroviral transduction and expression of p210bcr/abl. Blood 1992; 80:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/177\">",
"      Voncken JW, Morris C, Pattengale P, et al. Clonal development and karyotype evolution during leukemogenesis of BCR/ABL transgenic mice. Blood 1992; 79:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/178\">",
"      Canitrot Y, Lautier D, Laurent G, et al. Mutator phenotype of BCR--ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta. Oncogene 1999; 18:2676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/179\">",
"      Nishii K, Kabarowski JH, Gibbons DL, et al. ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. Oncogene 1996; 13:2225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/180\">",
"      Hoover RR, Gerlach MJ, Koh EY, Daley GQ. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells. Oncogene 2001; 20:5826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/181\">",
"      Slupianek A, Schmutte C, Tombline G, et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 2001; 8:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/182\">",
"      Sattler M, Verma S, Shrikhande G, et al. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 2000; 275:24273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/183\">",
"      Nowicki MO, Falinski R, Koptyra M, et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 2004; 104:3746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/184\">",
"      Viswanathan SR, Powers JT, Einhorn W, et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 2009; 41:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/185\">",
"      Kharas MG, Lengner CJ, Al-Shahrour F, et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med 2010; 16:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/186\">",
"      Ito T, Kwon HY, Zimdahl B, et al. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature 2010; 466:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/187\">",
"      Mashal R, Shtalrid M, Talpaz M, et al. Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia. Blood 1990; 75:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/188\">",
"      Honda H, Ushijima T, Wakazono K, et al. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML. Blood 2000; 95:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/189\">",
"      Radfar A, Unnikrishnan I, Lee HW, et al. p19(Arf) induces p53-dependent apoptosis during abelson virus-mediated pre-B cell transformation. Proc Natl Acad Sci U S A 1998; 95:13194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/190\">",
"      Williams RT, Roussel MF, Sherr CJ. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2006; 103:6688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/191\">",
"      Wang PY, Young F, Chen CY, et al. The biologic properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene. Blood 2008; 112:4184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/192\">",
"      Iacobucci I, Ferrari A, Lonetti A, et al. CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. Clin Cancer Res 2011; 17:7413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/193\">",
"      Huntly BJ, Reid AG, Bench AJ, et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001; 98:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/194\">",
"      de la Fuente J, Merx K, Steer EJ, et al. ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. Blood 2001; 98:2879.",
"     </a>",
"    </li>",
"    <li>",
"     Van Etten RA. Animal models of chronic myelogenous leukemia. In: Medical Management of Chronic Myelogenous Leukemia, Talpaz M, Kantarjian H (Eds), Marcel Dekker, New York 1998. p.77.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/196\">",
"      Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/197\">",
"      Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A 1990; 87:6649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/198\">",
"      Elefanty AG, Hariharan IK, Cory S. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J 1990; 9:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/199\">",
"      Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998; 92:3780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/200\">",
"      Zhang X, Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 1998; 92:3829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/201\">",
"      Daley GQ, Van Etten RA, Baltimore D. Blast crisis in a murine model of chronic myelogenous leukemia. Proc Natl Acad Sci U S A 1991; 88:11335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/202\">",
"      Gishizky ML, Johnson-White J, Witte ON. Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice. Proc Natl Acad Sci U S A 1993; 90:3755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/203\">",
"      Hu Y, Chen Y, Douglas L, Li S. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia 2009; 23:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/204\">",
"      Chen Y, Hu Y, Zhang H, et al. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet 2009; 41:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/205\">",
"      Nakahara F, Sakata-Yanagimoto M, Komeno Y, et al. Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia. Blood 2010; 115:2872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/206\">",
"      Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88:2375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/207\">",
"      Danhauser-Riedl S, Warmuth M, Druker BJ, et al. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res 1996; 56:3589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/208\">",
"      Hu Y, Liu Y, Pelletier S, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004; 36:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/209\">",
"      Ptasznik A, Nakata Y, Kalota A, et al. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med 2004; 10:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/210\">",
"      Hoelbl A, Schuster C, Kovacic B, et al. Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med 2010; 2:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/211\">",
"      Walz C, Ahmed W, Lazarides K, et al. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood 2012; 119:3550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/212\">",
"      Wolff NC, Ilaria RL Jr. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood 2001; 98:2808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/213\">",
"      Matte CC, Cormier J, Anderson BE, et al. Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing. Blood 2004; 103:4353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/214\">",
"      Lu YF, Gavrilescu LC, Betancur M, et al. Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model. Blood 2012; 119:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/215\">",
"      Hariharan IK, Harris AW, Crawford M, et al. A bcr-v-abl oncogene induces lymphomas in transgenic mice. Mol Cell Biol 1989; 9:2798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/216\">",
"      Heisterkamp N, Jenster G, Kioussis D, et al. Human bcr-abl gene has a lethal effect on embryogenesis. Transgenic Res 1991; 1:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/217\">",
"      Heisterkamp N, Jenster G, ten Hoeve J, et al. Acute leukaemia in bcr/abl transgenic mice. Nature 1990; 344:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/218\">",
"      Voncken JW, Kaartinen V, Pattengale PK, et al. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood 1995; 86:4603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/219\">",
"      Honda H, Fujii T, Takatoku M, et al. Expression of p210bcr/abl by metallothionein promoter induced T-cell leukemia in transgenic mice. Blood 1995; 85:2853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/220\">",
"      Voncken JW, Griffiths S, Greaves MF, et al. Restricted oncogenicity of BCR/ABL p190 in transgenic mice. Cancer Res 1992; 52:4534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/221\">",
"      Huettner CS, Zhang P, Van Etten RA, Tenen DG. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 2000; 24:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/222\">",
"      Koschmieder S, G&ouml;ttgens B, Zhang P, et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood 2005; 105:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/223\">",
"      Castellanos A, Pintado B, Weruaga E, et al. A BCR-ABL(p190) fusion gene made by homologous recombination causes B-cell acute lymphoblastic leukemias in chimeric mice with independence of the endogenous bcr product. Blood 1997; 90:2168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/224\">",
"      Voncken JW, Kaartinen V, Groffen J, Heisterkamp N. Bcr/Abl associated leukemogenesis in bcr null mutant mice. Oncogene 1998; 16:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/225\">",
"      Wang JC, Lapidot T, Cashman JD, et al. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood 1998; 91:2406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/33/40474/abstract/226\">",
"      Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999; 94:2056.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4487 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-201.65.114.212-1237D62C13-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_33_40474=[""].join("\n");
var outline_f39_33_40474=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6495922\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6496975\">",
"      CELL OF ORIGIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2792128\">",
"      Normal counterpart",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2791988\">",
"      The leukemia stem cell",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      THE BCR-ABL1 FUSION PROTEIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      BCR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      c-ABL1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      BCR-ABL1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2788069\">",
"      ESTABLISHMENT OF CHRONIC PHASE CML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2791725\">",
"      BCR-ABL1 signaling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2793041\">",
"      - Tyrosine kinase activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2793048\">",
"      - Kinase independent pathways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2788925\">",
"      Uncontrolled proliferation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2793233\">",
"      Discordant maturation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2788932\">",
"      Escape from apoptosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2788939\">",
"      Altered interaction with the cellular matrix",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7228199\">",
"      PROGRESSION TO ACUTE PHASE CML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4594144\">",
"      BCR-ABL1 activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4594151\">",
"      Differentiation arrest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7228376\">",
"      Genetic instability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4594219\">",
"      Inactivation of tumor suppressor genes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MOUSE MODELS OF CML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Retroviral transduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6496550\">",
"      Transgenic models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6496345\">",
"      Xenograft NOD/SCID model",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6495922\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4487\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4487|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/41/9886\" title=\"figure 1\">",
"      ABL1 and BCR genes in CML",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39114?source=related_link\">",
"      Chemotherapy for advanced exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19609?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/25/22938?source=related_link\">",
"      Cytogenetics in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19674?source=related_link\">",
"      Experimental treatment approaches for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25882?source=related_link\">",
"      Molecular genetics of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31512?source=related_link\">",
"      Molecular genetics of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/52/21322?source=related_link\">",
"      Overview of the myeloproliferative neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/16/41225?source=related_link\">",
"      Overview of the treatment of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44054?source=related_link\">",
"      Pathobiology of mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/33/35354?source=related_link\">",
"      Pathogenesis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/60/37829?source=related_link\">",
"      Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36730?source=related_link\">",
"      Prognosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_33_40475="Causes of FUO in pediatric HIV";
var content_f39_33_40475=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Important causes of FUO in HIV-infected children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Bacterial infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Occult focal bacterial infection (eg, sinusitis, pneumonia, internal abscess)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salmonellosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycobacterial infection (eg,",
"        <em>",
"         M. tuberculosis",
"        </em>",
"        ,",
"        <em>",
"         M. avium",
"        </em>",
"        complex,",
"        <em>",
"         M. kansasii",
"        </em>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Fungal infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disseminated cryptococcosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disseminated histoplasmosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumocystis jirovecii infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Occult focal fungal infection (eg, sinusitis, pneumonia, internal abscess)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Viral infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytomegalovirus infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epstein-Barr virus infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Herpes simplex virus infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Parasitic infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxoplasmosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoma and other types of malignancy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FUO: fever of unknown origin; HIV: human immunodeficiency virus.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_33_40475=[""].join("\n");
var outline_f39_33_40475=null;
var title_f39_33_40476="Int class retinoblastoma";
var content_f39_33_40476=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    International classification of retinoblastoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Subgroup",
"       </td>",
"       <td class=\"subtitle1\">",
"        Quick reference",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A",
"       </td>",
"       <td>",
"        A",
"       </td>",
"       <td>",
"        Small tumor",
"       </td>",
"       <td>",
"        Retinoblastoma &le;3 mm in size*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        B",
"       </td>",
"       <td rowspan=\"4\">",
"        B",
"       </td>",
"       <td>",
"        Larger tumor",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Retinoblastoma &gt;3 mm in size* or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Macula",
"       </td>",
"       <td class=\"sublist1\">",
"        Macular retinoblastoma location (&le;3 mm to foveola)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Juxtapapillary",
"       </td>",
"       <td class=\"sublist1\">",
"        Juxtapapillary retinoblastoma location (&le;1.5 mm to disc)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subretinal fluid",
"       </td>",
"       <td class=\"sublist1\">",
"        Clear subretinal fluid &le;3 mm from margin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        C",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"4\">",
"        Focal seeds",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Retinoblastoma with",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C1",
"       </td>",
"       <td class=\"sublist1\">",
"        Subretinal seeds &le;3 mm from retinoblastoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C2",
"       </td>",
"       <td class=\"sublist1\">",
"        Vitreous seeds &le;3 mm from retinoblastoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C3",
"       </td>",
"       <td class=\"sublist1\">",
"        Both subretinal and vitreous seeds &le;3 mm from retinoblastoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        D",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"4\">",
"        Diffuse seeds",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Retinoblastoma with",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D1",
"       </td>",
"       <td class=\"sublist1\">",
"        Subretinal seeds &gt;3 mm from retinoblastoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D2",
"       </td>",
"       <td class=\"sublist1\">",
"        Vitreous seeds &gt;3 mm from retinoblastoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D3",
"       </td>",
"       <td class=\"sublist1\">",
"        Both subretinal and vitreous seeds &gt;3 mm from retinoblastoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        E",
"       </td>",
"       <td rowspan=\"4\">",
"        E",
"       </td>",
"       <td rowspan=\"4\">",
"        Extensive retinoblastoma",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Extensive retinoblastoma occupying &gt;50 percent globe or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Neovascular glaucoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Opaque media from hemorrhage in anterior chamber, vitreous, or subretinal space",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Invasion of postlaminar optic nerve, choroid (&gt;2 mm), sclera, orbit, anterior chamber",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Refers to 3 mm in basal dimension or thickness.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Shields CL, Mashayekhi A, Au AK. The International Classification of Retinoblastoma Predicts Chemoreduction Success. Ophthalmology 2006; 113:2276. Copyright &copy;2006 American Academy of Ophthalmology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_33_40476=[""].join("\n");
var outline_f39_33_40476=null;
var title_f39_33_40477="NIH Stroke Scale";
var content_f39_33_40477=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F61698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F61698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    National Institutes of Health Stroke Scale (NIHSS)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         1a. Level of consciousness",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         0 = Alert and responsive",
"        </p>",
"        <p>",
"         1 = Arousable to minor stimulation",
"        </p>",
"        <p>",
"         2 = Arousable only to painful stimulation",
"        </p>",
"        <p>",
"         3 = Unarousable or reflex responses",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          1b. Questions",
"         </strong>",
"        </p>",
"        <p>",
"         Ask patient's age and month. Must be exact.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         0 = Both correct",
"        </p>",
"        <p>",
"         1 = One correct",
"        </p>",
"        <p>",
"         2 = Neither correct",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          1c. Commands",
"         </strong>",
"        </p>",
"        <p>",
"         Ask patient to open/close eyes, grip and release non-paretic hand.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         0 = Both correct",
"        </p>",
"        <p>",
"         1 = One correct",
"        </p>",
"        <p>",
"         2 = Neither correct",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          2. Best gaze",
"         </strong>",
"        </p>",
"        <p>",
"         Horizontal extraocular movements by voluntary or reflexive (oculocephalic maneuver) testing.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         0 = Normal",
"        </p>",
"        <p>",
"         1 = Partial gaze palsy; abnormal gaze in one or both eyes",
"        </p>",
"        <p>",
"         2 = Forced eye deviation or total paresis which cannot be overcome by oculocephalic maneuver",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          3. Visual fields",
"         </strong>",
"        </p>",
"        <p>",
"         Test by confrontation or threat as appropriate. If monocular, score field of good eye.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         0 = No visual loss",
"        </p>",
"        <p>",
"         1 = Partial hemianopia, quadrantanopia, extinction",
"        </p>",
"        <p>",
"         2 = Complete hemianopia",
"        </p>",
"        <p>",
"         3 = Bilateral hemianopia or blindness",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          4. Facial palsy",
"         </strong>",
"        </p>",
"        <p>",
"         If stuporous, check symmetry of grimace to pain. Paralysis (lower face).",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         0 = Normal",
"        </p>",
"        <p>",
"         1 = Minor paralysis (normal looking face, asymmetric smile)",
"        </p>",
"        <p>",
"         2 = Partial paralysis",
"        </p>",
"        <p>",
"         3 = Complete paralysis (upper and lower face)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          5a. Left motor arm",
"         </strong>",
"        </p>",
"        <p>",
"         <strong>",
"          5b. Right motor arm",
"         </strong>",
"        </p>",
"        <p>",
"         Arms outstretched 90&deg; (if patient is sitting) or 45&deg; (if supine) for 10 seconds. Encourage best effort, note paretic side.",
"        </p>",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         0 = No drift",
"        </p>",
"        <p>",
"         1 = Drift but does not hit bed",
"        </p>",
"        <p>",
"         2 = Some antigravity effort, but cannot sustain",
"        </p>",
"        <p>",
"         3 = No antigravity effort, but minimal movement present",
"        </p>",
"        <p>",
"         4 = No movement at all",
"        </p>",
"        <p>",
"         X = Unable to assess due to amputation, fusion, etc",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          6a. Left motor leg",
"         </strong>",
"        </p>",
"        <p>",
"         <strong>",
"          6b. Right motor leg",
"         </strong>",
"        </p>",
"        <p>",
"         Raise leg to 30&deg; (always test patient supine) for 5 seconds.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          7. Limb ataxia",
"         </strong>",
"        </p>",
"        <p>",
"         Check finger-nose-finger; heel-shin; score only if out of proportion to weakness.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         0 = No ataxia (or aphasic, hemiplegic)",
"        </p>",
"        <p>",
"         1 = Ataxia present in one limb",
"        </p>",
"        <p>",
"         2 = Ataxia present in two limbs",
"        </p>",
"        <p>",
"         X = Unable to assess as above",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          8. Sensory",
"         </strong>",
"        </p>",
"        <p>",
"         Use safety pin. Check grimace or withdrawal if stuporous. Score only stroke related losses.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         0 = Normal",
"        </p>",
"        <p>",
"         1 = Mild to moderate unilateral sensory loss but patient aware of touch",
"        </p>",
"        <p>",
"         2 = Severe to total sensory loss, patient unaware of touch (or bilateral sensory loss or comatose)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          9. Best language",
"         </strong>",
"        </p>",
"        <p>",
"         Ask patient to describe cookie jar picture, name objects, read sentences. May use repeating, writing, stereognosis.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         0 = Normal",
"        </p>",
"        <p>",
"         1 = Mild-moderate aphasia",
"        </p>",
"        <p>",
"         2 = Severe aphasia (almost no information exchanged)",
"        </p>",
"        <p>",
"         3 = Mute, global aphasia, or coma",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          10. Dysarthria",
"         </strong>",
"        </p>",
"        <p>",
"         Ask patient to read or repeat a list of words.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         0 = Normal",
"        </p>",
"        <p>",
"         1 = Mild-moderate dysarthria",
"        </p>",
"        <p>",
"         2 = Severe, unintelligible or mute",
"        </p>",
"        <p>",
"         X = Intubation or mechanical barrier",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          11. Extinction and inattention",
"         </strong>",
"        </p>",
"        <p>",
"         Simultaneously touch patient on both hands, show fingers in both visual fields, ask patient to describe deficit, left hand.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         0 = Normal, none detected (or severe visual loss with normal cutaneous responses)",
"        </p>",
"        <p>",
"         1 = Neglects or extinguishes to bilateral simultaneous stimulation in any sensory modality (visual, tactile, auditory, spatial, or personal inattention)",
"        </p>",
"        <p>",
"         2 = Profound hemi-inattention or extinction in more than one modality",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Goldstein LB, Samsa GP, Stroke 1997; 28:307.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_33_40477=[""].join("\n");
var outline_f39_33_40477=null;
var title_f39_33_40478="Sigmoid pull through colostomy";
var content_f39_33_40478=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sigmoid pull through colostomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 202px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A loop of sigmoid colon is pulled through the incision.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_33_40478=[""].join("\n");
var outline_f39_33_40478=null;
var title_f39_33_40479="RTT prior to developmental arrest";
var content_f39_33_40479=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rett syndrome prior to developmental arrest",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    At six months of age, this girl with RTT appears normal and has animated facial expression.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Glaze DG, Schultz RJ. Rett syndrome: meeting the challenge of this gender-specific neurodevelopmental disorder. Medscape Women's Health 1997; 2. Copyright &copy; 1997 Medscape.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_33_40479=[""].join("\n");
var outline_f39_33_40479=null;
